The pharmacology of resveratrol in animals and humans

Biochimica et Biophysica Acta - Molecular Basis of Disease

Volumn 1852, Issue 6, 2015, Pages 1071-1113

  Park, Eun Jung ^a   Pezzuto, John M ^a  

^a UNIVERSITY OF HAWAII AT HILO   (United States)

Author keywords

Animal study; Clinical trial; Pharmacological activity; Resveratrol

Indexed keywords

RESVERATROL; STILBENES;

ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; PERIODICALS AS TOPIC;

ANIMALS; CLINICAL TRIALS AS TOPIC; HUMANS; PERIODICALS AS TOPIC; STILBENES;

EID: 84938104525     PISSN: 09254439     EISSN: 1879260X     Source Type: Journal    
DOI: 10.1016/j.bbadis.2015.01.014     Document Type: Article

References (381)

1. Takaoka M. Resveratrol, a new phenolic compound, from Veratrum grandiflorum. J. Chem. Soc. Jpn. 1939, 60(1):1090-1100.
2. Giovinazzo G., Ingrosso I., Paradiso A., De Gara L., Santino A. Resveratrol biosynthesis: plant metabolic engineering for nutritional improvement of food. Plant Foods Hum. Nutr. 2012, 67(3):191-199.
3. Jeandet P., Delaunois B., Aziz A., Donnez D., Vasserot Y., Cordelier S., Courot E. Metabolic engineering of yeast and plants for the production of the biologically active hydroxystilbene, resveratrol. J. Biomed. Biotechnol. 2012, 2012:579089.
4. Renaud S., de Lorgeril M. Wine, alcohol, platelets, and the French paradox for coronary heart disease. Lancet 1992, 339(8808):1523-1526.
5. Siemann E.H., Creasy L.L. Concentration of the phytoalexin resveratrol in wine. Am. J. Enol. Vitic. 1992, 43(1):49-52.
6. Guilford J.M., Pezzuto J.M. Wine and health: a review. Am. J. Enol. Vitic. 2011, 62(4):471-486.
7. Pezzuto J.M. Grapes and human health: a perspective. J. Agric. Food Chem. 2008, 56(16):6777-6784.
8. Jang M., Cai L., Udeani G.O., Slowing K.V., Thomas C.F., Beecher C.W., Fong H.H., Farnsworth N.R., Kinghorn A.D., Mehta R.G., et al. Cancer chemopreventive activity of resveratrol, a natural product derived from grapes. Science 1997, 275(5297):218-220.
9. Pezzuto J.M., Kondratyuk T.P., Ogas T. Resveratrol derivatives: a patent review (2009-2012). Expert Opin. Ther. Pat. 2013, 23(12):1529-1546.
10. Ruggeri B.A., Camp F., Miknyoczki S. Animal models of disease: pre-clinical animal models of cancer and their applications and utility in drug discovery. Biochem. Pharmacol. 2014, 87(1):150-161.
11. Steele V.E., Lubet R.A., Moon R.C. Preclinical Animal Models for the Development of Cancer Chemoprevention Drugs 2005, Humana Press Inc., Totowa, NJ.
12. Kapadia G.J., Azuine M.A., Tokuda H., Takasaki M., Mukainaka T., Konoshima T., Nishino H. Chemopreventive effect of resveratrol, sesamol, sesame oil and sunflower oil in the Epstein-Barr virus early antigen activation assay and the mouse skin two-stage carcinogenesis. Pharmacol. Res. 2002, 45(6):499-505.
13. Soleas G.J., Grass L., Josephy P.D., Goldberg D.M., Diamandis E.P. A comparison of the anticarcinogenic properties of four red wine polyphenols. Clin. Biochem. 2002, 35(2):119-124.
14. Kalra N., Roy P., Prasad S., Shukla Y. Resveratrol induces apoptosis involving mitochondrial pathways in mouse skin tumorigenesis. Life Sci. 2008, 82(7-8):348-358.
15. Boily G., He X.H., Pearce B., Jardine K., McBurney M.W. SirT1-null mice develop tumors at normal rates but are poorly protected by resveratrol. Oncogene 2009, 28(32):2882-2893.
16. Kowalczyk M.C., Junco J.J., Kowalczyk P., Tolstykh O., Hanausek M., Slaga T.J., Walaszek Z. Effects of combined phytochemicals on skin tumorigenesis in SENCAR mice. Int. J. Oncol. 2013, 43(3):911-918.
17. Roy P., Kalra N., Prasad S., George J., Shukla Y. Chemopreventive potential of resveratrol in mouse skin tumors through regulation of mitochondrial and PI3K/AKT signaling pathways. Pharm. Res. 2009, 26(1):211-217.
18. Szaefer H., Krajka-Kuźniak V., Baer-Dubowska W. The effect of initiating doses of benzo[a]pyrene and 7,12-dimethylbenz[a]anthracene on the expression of PAH activating enzymes and its modulation by plant phenols. Toxicology 2008, 251(1-3):28-34.
19. Yusuf N., Nasti T.H., Meleth S., Elmets C.A. Resveratrol enhances cell-mediated immune response to DMBA through TLR4 and prevents DMBA induced cutaneous carcinogenesis. Mol. Carcinog. 2009, 48(8):713-723.
20. Kowalczyk M.C., Walaszek Z., Kowalczyk P., Kinjo T., Hanausek M., Slaga T.J. Differential effects of several phytochemicals and their derivatives on murine keratinocytes in vitro and in vivo: implications for skin cancer prevention. Carcinogenesis 2009, 30(6):1008-1015.
21. Kowalczyk M.C., Kowalczyk P., Tolstykh O., Hanausek M., Walaszek Z., Slaga T.J. Synergistic effects of combined phytochemicals and skin cancer prevention in SENCAR mice. Cancer Prev. Res. (Phila.) 2010, 3(2):170-178.
22. Jang M., Pezzuto J.M. Effects of resveratrol on 12-O-tetradecanoylphorbol-13-acetate-induced oxidative events and gene expression in mouse skin. Cancer Lett. 1998, 134(1):81-89.
23. Kundu J.K., Chun K.S., Kim S.O., Surh Y.J. Resveratrol inhibits phorbol ester-induced cyclooxygenase-2 expression in mouse skin: MAPKs and AP-1 as potential molecular targets. Biofactors 2004, 21(1-4):33-39.
24. Cichocki M., Paluszczak J., Szaefer H., Piechowiak A., Rimando A.M., Baer-Dubowska W. Pterostilbene is equally potent as resveratrol in inhibiting 12-O-tetradecanoylphorbol-13-acetate activated NFkappaB, AP-1, COX-2, and iNOS in mouse epidermis. Mol. Nutr. Food Res. 2008, 52(Suppl. 1):S62-S70.
25. Fu Z.D., Cao Y., Wang K.F., Xu S.F., Han R. Chemopreventive effect of resveratrol to cancer. Ai Zheng 2004, 23(8):869-873.
26. Afaq F., Adhami V.M., Ahmad N. Prevention of short-term ultraviolet B radiation-mediated damages by resveratrol in SKH-1 hairless mice. Toxicol. Appl. Pharmacol. 2003, 186(1):28-37.
27. Reagan-Shaw S., Afaq F., Aziz M.H., Ahmad N. Modulations of critical cell cycle regulatory events during chemoprevention of ultraviolet B-mediated responses by resveratrol in SKH-1 hairless mouse skin. Oncogene 2004, 23(30):5151-5160.
28. Aziz M.H., Reagan-Shaw S., Wu J., Longley B.J., Ahmad N. Chemoprevention of skin cancer by grape constituent resveratrol: relevance to human disease?. FASEB J. 2005, 19(9):1193-1195.
29. Kim K.H., Back J.H., Zhu Y., Arbesman J., Athar M., Kopelovich L., Kim A.L., Bickers D.R. Resveratrol targets transforming growth factor-β2 signaling to block UV-induced tumor progression. J. Invest. Dermatol. 2011, 131(1):195-202.
30. Hao Y., Huang W., Liao M., Zhu Y., Liu H., Hao C., Liu G., Zhang G., Feng H., Ning X., et al. The inhibition of resveratrol to human skin squamous cell carcinoma A431 xenografts in nude mice. Fitoterapia 2013, 86:84-91.
31. Back J.H., Zhu Y., Calabro A., Queenan C., Kim A.S., Arbesman J., Kim A.L. Resveratrol-mediated downregulation of Rictor attenuates autophagic process and suppresses UV-induced skin carcinogenesis. Photochem. Photobiol. 2012, 88(5):1165-1172.
32. Hao Y.Q., Huang W.X., Feng H.X., Zhang G.H., Ning X.H., Li H.G., Hao C.G., Li Z.H. Study of apoptosis related factors regulatory mechanism of resveratrol to human skin squamous cell carcinoma A431 xenograft in nude mice. Zhonghua Yi Xue Za Zhi 2013, 93(6):464-468.
33. Bhattacharya S., Darjatmoko S.R., Polans A.S. Resveratrol modulates the malignant properties of cutaneous melanoma through changes in the activation and attenuation of the antiapoptotic protooncogenic protein Akt/PKB. Melanoma Res. 2011, 21(3):180-187.
34. Lee H., Zhang P., Herrmann A., Yang C., Xin H., Wang Z., Hoon D.S., Forman S.J., Jove R., Riggs A.D., et al. Acetylated STAT3 is crucial for methylation of tumor-suppressor gene promoters and inhibition by resveratrol results in demethylation. Proc. Natl. Acad. Sci. U. S. A. 2012, 109(20):7765-7769.
35. Asensi M., Medina I., Ortega A., Carretero J., Baño M.C., Obrador E., Estrela J.M. Inhibition of cancer growth by resveratrol is related to its low bioavailability. Free Radic. Biol. Med. 2002, 33(3):387-398.
36. Niles R.M., Cook C.P., Meadows G.G., Fu Y.M., McLaughlin J.L., Rankin G.O. Resveratrol is rapidly metabolized in athymic (nu/nu) mice and does not inhibit human melanoma xenograft tumor growth. J. Nutr. 2006, 136(10):2542-2546.
37. Osmond G.W., Masko E.M., Tyler D.S., Freedland S.J., Pizzo S. In vitro and in vivo evaluation of resveratrol and 3,5-dihydroxy-4'-acetoxy-trans-stilbene in the treatment of human prostate carcinoma and melanoma. J. Surg. Res. 2013, 179(1):e141-e148.
38. Lee T.H., Seo J.O., Baek S.H., Kim S.Y. Inhibitory effects of resveratrol on melanin synthesis in ultraviolet B-induced pigmentation in Guinea pig skin. Biomol. Ther. (Seoul) 2014, 22(1):35-40.
39. Siegel R., Ma J., Zou Z., Jemal A. Cancer statistics, 2014. CA Cancer J Clin. 2014, 64(1):9-29.
40. Bhat K.P., Lantvit D., Christov K., Mehta R.G., Moon R.C., Pezzuto J.M. Estrogenic and antiestrogenic properties of resveratrol in mammary tumor models. Cancer Res. 2001, 61(20):7456-7463.
41. Qin W., Zhang K., Clarke K., Weiland T., Sauter E.R. Methylation and miRNA effects of resveratrol on mammary tumors vs. normal tissue. Nutr. Cancer 2014, 66(2):270-277.
42. Provinciali M., Re F., Donnini A., Orlando F., Bartozzi B., Di Stasio G., Smorlesi A. Effect of resveratrol on the development of spontaneous mammary tumors in HER-2/neu transgenic mice. Int. J. Cancer 2005, 115(1):36-45.
43. Zander S.A., Kersbergen A., Sol W., Gonggrijp M., van de Wetering K., Jonkers J., Borst P., Rottenberg S. Lack of ABCG2 shortens latency of BRCA1-deficient mammary tumors and this is not affected by genistein or resveratrol. Cancer Prev. Res. (Phila.) 2012, 5(8):1053-1060.
44. Bove K., Lincoln D.W., Tsan M.F. Effect of resveratrol on growth of 4T1 breast cancer cells in vitro and in vivo. Biochem. Biophys. Res. Commun. 2002, 291(4):1001-1005.
45. Sato M., Pei R.J., Yuri T., Danbara N., Nakane Y., Tsubura A. Prepubertal resveratrol exposure accelerates N-methyl-N-nitrosourea-induced mammary carcinoma in female Sprague-Dawley rats. Cancer Lett. 2003, 202(2):137-145.
46. Castillo-Pichardo L., Cubano L.A., Dharmawardhane S. Dietary grape polyphenol resveratrol increases mammary tumor growth and metastasis in immunocompromised mice. BMC Complement. Altern. Med. 2013, 13:6.
47. Whitsett T., Carpenter M., Lamartiniere C.A. Resveratrol, but not EGCG, in the diet suppresses DMBA-induced mammary cancer in rats. J. Carcinog. 2006, 5:15.
48. Garvin S., Ollinger K., Dabrosin C. Resveratrol induces apoptosis and inhibits angiogenesis in human breast cancer xenografts in vivo. Cancer Lett. 2006, 231(1):113-122.
49. Barbara B., Andrzej T., Grzegorz G., Slawomir B., Matysiak M., Bat-Erdene T. The effect of polyphenols on markers of oxidative damage and DMBA-induced carcinogenesis in rats. J. Food Lipids 2009, 16(1):103-112.
50. Mohapatra P., Satapathy S.R., Das D., Siddharth S., Choudhuri T., Kundu C.N. Resveratrol mediated cell death in cigarette smoke transformed breast epithelial cells is through induction of p21Waf1/Cip1 and inhibition of long patch base excision repair pathway. Toxicol. Appl. Pharmacol. 2014, 275(3):221-231.
51. Fu Y., Chang H., Peng X., Bai Q., Yi L., Zhou Y., Zhu J., Mi M. Resveratrol inhibits breast cancer stem-like cells and induces autophagy via suppressing Wnt/β-catenin signaling pathway. PLoS ONE 2014, 9(7):e102535.
52. Banerjee S., Bueso-Ramos C., Aggarwal B.B. Suppression of 7,12-dimethylbenz(a)anthracene-induced mammary carcinogenesis in rats by resveratrol: role of nuclear factor-kappaB, cyclooxygenase 2, and matrix metalloprotease 9. Cancer Res. 2002, 62(17):4945-4954.
53. Chatterjee M., Das S., Janarthan M., Ramachandran H.K. Role of 5-lipoxygenase in resveratrol mediated suppression of 7,12-dimethylbenz(α)anthracene-induced mammary carcinogenesis in rats. Eur. J. Pharmacol. 2011, 668(1-2):99-106.
54. Pandey P.R., Okuda H., Watabe M., Pai S.K., Liu W., Kobayashi A., Xing F., Fukuda K., Hirota S., Sugai T., et al. Resveratrol suppresses growth of cancer stem-like cells by inhibiting fatty acid synthase. Breast Cancer Res. Treat. 2011, 130(2):387-398.
55. Papoutsis A.J., Selmin O.I., Borg J.L., Romagnolo D.F. Gestational exposure to the AhR agonist 2,3,7,8-tetrachlorodibenzo-p-dioxin induces BRCA-1 promoter hypermethylation and reduces BRCA-1 expression in mammary tissue of rat offspring: preventive effects of resveratrol. Mol. Carcinog. 2013, [Epub ahead of print]. 10.1002/mc.22095.
56. Harper C.E., Patel B.B., Wang J., Arabshahi A., Eltoum I.A., Lamartiniere C.A. Resveratrol suppresses prostate cancer progression in transgenic mice. Carcinogenesis 2007, 28(9):1946-1953.
57. Seeni A., Takahashi S., Takeshita K., Tang M., Sugiura S., Sato S.Y., Shirai T. Suppression of prostate cancer growth by resveratrol in the transgenic rat for adenocarcinoma of prostate (TRAP) model. Asian Pac. J. Cancer Prev. 2008, 9(1):7-14.
58. Harper C.E., Cook L.M., Patel B.B., Wang J., Eltoum I.A., Arabshahi A., Shirai T., Lamartiniere C.A. Genistein and resveratrol, alone and in combination, suppress prostate cancer in SV-40 tag rats. Prostate 2009, 69(15):1668-1682.
59. Narayanan N.K., Nargi D., Randolph C., Narayanan B.A. Liposome encapsulation of curcumin and resveratrol in combination reduces prostate cancer incidence in PTEN knockout mice. Int. J. Cancer 2009, 125(1):1-8.
60. Li G., Rivas P., Bedolla R., Thapa D., Reddick R.L., Ghosh R., Kumar A.P. Dietary resveratrol prevents development of high-grade prostatic intraepithelial neoplastic lesions: involvement of SIRT1/S6K axis. Cancer Prev. Res. (Phila.) 2013, 6(1):27-39.
61. Wang T.T., Hudson T.S., Wang T.C., Remsberg C.M., Davies N.M., Takahashi Y., Kim Y.S., Seifried H., Vinyard B.T., Perkins S.N., et al. Differential effects of resveratrol on androgen-responsive LNCaP human prostate cancer cells in vitro and in vivo. Carcinogenesis 2008, 29(10):2001-2010.
62. Dias S.J., Li K., Rimando A.M., Dhar S., Mizuno C.S., Penman A.D., Levenson A.S. Trimethoxy-resveratrol and piceatannol administered orally suppress and inhibit tumor formation and growth in prostate cancer xenografts. Prostate 2013, 73(11):1135-1146.
63. Klink J.C., Tewari A.K., Masko E.M., Antonelli J., Febbo P.G., Cohen P., Dewhirst M.W., Pizzo S.V., Freedland S.J. Resveratrol worsens survival in SCID mice with prostate cancer xenografts in a cell-line specific manner, through paradoxical effects on oncogenic pathways. Prostate 2013, 73(7):754-762.
64. Mitani T., Harada N., Tanimori S., Nakano Y., Inui H., Yamaji R. Resveratrol inhibits hypoxia-inducible factor-1α-mediated androgen receptor signaling and represses tumor progression in castration-resistant prostate cancer. J. Nutr. Sci. Vitaminol. (Tokyo) 2014, 60(4):276-282.
65. Ganapathy S., Chen Q., Singh K.P., Shankar S., Srivastava R.K. Resveratrol enhances antitumor activity of TRAIL in prostate cancer xenografts through activation of FOXO transcription factor. PLoS ONE 2010, 5(12):e15627.
66. Brizuela L., Dayon A., Doumerc N., Ader I., Golzio M., Izard J.C., Hara Y., Malavaud B., Cuvillier O. The sphingosine kinase-1 survival pathway is a molecular target for the tumor-suppressive tea and wine polyphenols in prostate cancer. FASEB J. 2010, 24(10):3882-3894.
67. Li K., Dias S.J., Rimando A.M., Dhar S., Mizuno C.S., Penman A.D., Lewin J.R., Levenson A.S. Pterostilbene acts through metastasis-associated protein 1 to inhibit tumor growth, progression and metastasis in prostate cancer. PLoS ONE 2013, 8(3):e57542.
68. Sheth S., Jajoo S., Kaur T., Mukherjea D., Sheehan K., Rybak L.P., Ramkumar V. Resveratrol reduces prostate cancer growth and metastasis by inhibiting the Akt/MicroRNA-21 pathway. PLoS ONE 2012, 7(12):e51655.
69. Hecht S.S., Kenney P.M., Wang M., Trushin N., Agarwal S., Rao A.V., Upadhyaya P. Evaluation of butylated hydroxyanisole, myo-inositol, curcumin, esculetin, resveratrol and lycopene as inhibitors of benzo[a]pyrene plus 4-(methylnitrosamino)-1-(3-pyridyl)-1-butanone-induced lung tumorigenesis in A/J mice. Cancer Lett. 1999, 137(2):123-130.
70. Berge G., Øvrebø S., Eilertsen E., Haugen A., Mollerup S. Analysis of resveratrol as a lung cancer chemopreventive agent in A/J mice exposed to benzo[a]pyrene. Br. J. Cancer 2004, 91(7):1380-1383.
71. Revel A., Raanani H., Younglai E., Xu J., Rogers I., Han R., Savouret J.F., Casper R.F. Resveratrol, a natural aryl hydrocarbon receptor antagonist, protects lung from DNA damage and apoptosis caused by benzo[a]pyrene. J. Appl. Toxicol. 2003, 23(4):255-261.
72. Malhotra A., Nair P., Dhawan D.K. Premature mitochondrial senescence and related ultrastructural changes during lung carcinogenesis modulation by curcumin and resveratrol. Ultrastruct. Pathol. 2012, 36(3):179-184.
73. Malhotra A., Nair P., Dhawan D.K. Study to evaluate molecular mechanics behind synergistic chemo-preventive effects of curcumin and resveratrol during lung carcinogenesis. PLoS ONE 2014, 9(4):e93820.
74. Kimura Y., Okuda H. Resveratrol isolated from Polygonum cuspidatum root prevents tumor growth and metastasis to lung and tumor-induced neovascularization in Lewis lung carcinoma-bearing mice. J. Nutr. 2001, 131(6):1844-1849.
75. Lee E.O., Lee H.J., Hwang H.S., Ahn K.S., Chae C., Kang K.S., Lu J., Kim S.H. Potent inhibition of Lewis lung cancer growth by heyneanol A from the roots of Vitis amurensis through apoptotic and anti-angiogenic activities. Carcinogenesis 2006, 27(10):2059-2069.
76. Yang K., He J., Zhang P. Inhibitory effects of resveratrol on growth of lewis lung cancer cell in mice and possible mechanism. Zhongliu Fangzhi Yanjiu 2011, 38(8):871-874.
77. Chen X.-p., Feng L. Inhibitory effect of resveratrol on tumor growth in Lewis C57BL6J and its antioxidation activity in vivo and in vitro. Zhongguo Yiyuan Yaoxue Zazhi 2012, 32(21):1696-1699.
78. Yin H.T., Tian Q.Z., Guan L., Zhou Y., Huang X.E., Zhang H. In vitro and in vivo evaluation of the antitumor efficiency of resveratrol against lung cancer. Asian Pac. J. Cancer Prev. 2013, 14(3):1703-1706.
79. Yu Y.H., Chen H.A., Chen P.S., Cheng Y.J., Hsu W.H., Chang Y.W., Chen Y.H., Jan Y., Hsiao M., Chang T.Y., et al. MiR-520h-mediated FOXC2 regulation is critical for inhibition of lung cancer progression by resveratrol. Oncogene 2013, 32(4):431-443.
80. Lee K.A., Lee Y.J., Ban J.O., Lee S.H., Cho M.K., Nam H.S., Hong J.T., Shim J.H. The flavonoid resveratrol suppresses growth of human malignant pleural mesothelioma cells through direct inhibition of specificity protein 1. Int. J. Mol. Med. 2012, 30(1):21-27.
81. Jung K.H., Lee J.H., Thien Quach C.H., Paik J.Y., Oh H., Park J.W., Lee E.J., Moon S.H., Lee K.H. Resveratrol suppresses cancer cell glucose uptake by targeting reactive oxygen species-mediated hypoxia-inducible factor-1α activation. J. Nucl. Med. 2013, 54(12):2161-2167.
82. Washington M.K., Powell A.E., Sullivan R., Sundberg J.P., Wright N., Coffey R.J., Dove W.F. Pathology of rodent models of intestinal cancer: progress report and recommendations. Gastroenterology 2013, 144(4):705-717.
83. Cui X., Jin Y., Hofseth A.B., Pena E., Habiger J., Chumanevich A., Poudyal D., Nagarkatti M., Nagarkatti P.S., Singh U.P., et al. Resveratrol suppresses colitis and colon cancer associated with colitis. Cancer Prev. Res. (Phila.) 2010, 3(4):549-559.
84. Liao W., Wei H., Wang X., Qiu Y., Gou X., Zhang X., Zhou M., Wu J., Wu T., Kou F., et al. Metabonomic variations associated with AOM-induced precancerous colorectal lesions and resveratrol treatment. J. Proteome Res. 2012, 11(6):3436-3448.
85. Tessitore L., Davit A., Sarotto I., Caderni G. Resveratrol depresses the growth of colorectal aberrant crypt foci by affecting bax and p21(CIP) expression. Carcinogenesis 2000, 21(8):1619-1622.
86. Chiou Y.S., Tsai M.L., Nagabhushanam K., Wang Y.J., Wu C.H., Ho C.T., Pan M.H. Pterostilbene is more potent than resveratrol in preventing azoxymethane (AOM)-induced colon tumorigenesis via activation of the NF-E2-related factor 2 (Nrf2)-mediated antioxidant signaling pathway. J. Agric. Food Chem. 2011, 59(6):2725-2733.
87. Sengottuvelan M., Nalini N. Dietary supplementation of resveratrol suppresses colonic tumour incidence in 1,2-dimethylhydrazine-treated rats by modulating biotransforming enzymes and aberrant crypt foci development. Br. J. Nutr. 2006, 96(1):145-153.
88. Sengottuvelan M., Senthilkumar R., Nalini N. Modulatory influence of dietary resveratrol during different phases of 1,2-dimethylhydrazine induced mucosal lipid-peroxidation, antioxidant status and aberrant crypt foci development in rat colon carcinogenesis. Biochim. Biophys. Acta 2006, 1760(8):1175-1183.
89. Alfaras I., Juan M.E., Planas J.M. trans-Resveratrol reduces precancerous colonic lesions in dimethylhydrazine-treated rats. J. Agric. Food Chem. 2010, 58(13):8104-8110.
90. Sengottuvelan M., Deeptha K., Nalini N. Resveratrol ameliorates DNA damage, prooxidant and antioxidant imbalance in 1,2-dimethylhydrazine induced rat colon carcinogenesis. Chem. Biol. Interact. 2009, 181(2):193-201.
91. Sengottuvelan M., Viswanathan P., Nalini N. Chemopreventive effect of trans-resveratrol-a phytoalexin against colonic aberrant crypt foci and cell proliferation in 1,2-dimethylhydrazine induced colon carcinogenesis. Carcinogenesis 2006, 27(5):1038-1046.
92. Sengottuvelan M., Deeptha K., Nalini N. Influence of dietary resveratrol on early and late molecular markers of 1,2-dimethylhydrazine-induced colon carcinogenesis. Nutrition 2009, 25(11-12):1169-1176.
93. Doustar Y., Garjani A. Immunohistochemical study of the effect of resveratrol on the expression of β-catenin protein in experimental colonic carcinoma of rat. J. Anim. Vet. Adv. 2012, 11(23):4472-4475.
94. Schneider Y., Duranton B., Gossé F., Schleiffer R., Seiler N., Raul F. Resveratrol inhibits intestinal tumorigenesis and modulates host-defense-related gene expression in an animal model of human familial adenomatous polyposis. Nutr. Cancer 2001, 39(1):102-107.
95. Sale S., Tunstall R.G., Ruparelia K.C., Potter G.A., Steward W.P., Gescher A.J. Comparison of the effects of the chemopreventive agent resveratrol and its synthetic analog trans 3,4,5,4'-tetramethoxystilbene (DMU-212) on adenoma development in the Apc(Min+) mouse and cyclooxygenase-2 in human-derived colon cancer cells. Int. J. Cancer 2005, 115(2):194-201.
96. Huderson A.C., Myers J.N., Niaz M.S., Washington M.K., Ramesh A. Chemoprevention of benzo(a)pyrene-induced colon polyps in ApcMin mice by resveratrol. J. Nutr. Biochem. 2013, 24(4):713-724.
97. Saud S.M., Li W., Morris N.L., Matter M.S., Colburn N.H., Kim Y.S., Young M.R. Resveratrol prevents tumorigenesis in mouse model of Kras activated sporadic colorectal cancer by suppressing oncogenic Kras expression. Carcinogenesis 2014, 35(12):2778-2786.
98. Ziegler C.C., Rainwater L., Whelan J., McEntee M.F. Dietary resveratrol does not affect intestinal tumorigenesis in Apc(Min/+) mice. J. Nutr. 2004, 134(1):5-10.
99. Bakiri L., Wagner E.F. Mouse models for liver cancer. Mol. Oncol. 2013, 7(2):206-223.
100. Bishayee A., Dhir N. Resveratrol-mediated chemoprevention of diethylnitrosamine-initiated hepatocarcinogenesis: inhibition of cell proliferation and induction of apoptosis. Chem. Biol. Interact. 2009, 179(2-3):131-144.
101. Luther D.J., Ohanyan V., Shamhart P.E., Hodnichak C.M., Sisakian H., Booth T.D., Meszaros J.G., Bishayee A. Chemopreventive doses of resveratrol do not produce cardiotoxicity in a rodent model of hepatocellular carcinoma. Invest. New Drugs 2011, 29(2):380-391.
102. Mbimba T., Awale P., Bhatia D., Geldenhuys W.J., Darvesh A.S., Carroll R.T., Bishayee A. Alteration of hepatic proinflammatory cytokines is involved in the resveratrol-mediated chemoprevention of chemically-induced hepatocarcinogenesis. Curr. Pharm. Biotechnol. 2012, 13(1):229-234.
103. Bishayee A., Barnes K.F., Bhatia D., Darvesh A.S., Carroll R.T. Resveratrol suppresses oxidative stress and inflammatory response in diethylnitrosamine-initiated rat hepatocarcinogenesis. Cancer Prev. Res. (Phila.) 2010, 3(6):753-763.
104. Rajasekaran D., Elavarasan J., Sivalingam M., Ganapathy E., Kumar A., Kalpana K., Sakthisekaran D. Resveratrol interferes with N-nitrosodiethylamine-induced hepatocellular carcinoma at early and advanced stages in male Wistar rats. Mol. Med. Rep. 2011, 4(6):1211-1217.
105. Wu X., Li C., Xing G., Qi X., Ren J. Resveratrol downregulates Cyp2e1 and attenuates chemically induced hepatocarcinogenesis in SD rats. J. Toxicol. Pathol. 2013, 26(4):385-392.
106. Lin H.C., Chen Y.F., Hsu W.H., Yang C.W., Kao C.H., Tsai T.F. Resveratrol helps recovery from fatty liver and protects against hepatocellular carcinoma induced by hepatitis B virus X protein in a mouse model. Cancer Prev. Res. (Phila.) 2012, 5(7):952-962.
107. Carbó N., Costelli P., Baccino F.M., López-Soriano F.J., Argilés J.M. Resveratrol, a natural product present in wine, decreases tumour growth in a rat tumour model. Biochem. Biophys. Res. Commun. 1999, 254(3):739-743.
108. Liu H.S., Pan C.E., Yang W., Liu X.M. Antitumor and immunomodulatory activity of resveratrol on experimentally implanted tumor of H22 in Balb/c mice. World J. Gastroenterol. 2003, 9(7):1474-1476.
109. Yu L., Sun Z.J., Wu S.L., Pan C.E. Effect of resveratrol on cell cycle proteins in murine transplantable liver cancer. World J. Gastroenterol. 2003, 9(10):2341-2343.
110. Miura D., Miura Y., Yagasaki K. Hypolipidemic action of dietary resveratrol, a phytoalexin in grapes and red wine, in hepatoma-bearing rats. Life Sci. 2003, 73(11):1393-1400.
111. Li T., Wang W. [The mechanism of resveratrol on anti-hepatoma Bel-7402 and modulating IL-8 in tumor model mice]. Zhong Yao Cai 2008, 31(5):697-702.
112. Yang H.L., Chen W.Q., Cao X., Worschech A., Du L.F., Fang W.Y., Xu Y.Y., Stroncek D.F., Li X., Wang E., et al. Caveolin-1 enhances resveratrol-mediated cytotoxicity and transport in a hepatocellular carcinoma model. J. Transl. Med. 2009, 7:22.
113. Yu H.B., Zhang H.F., Zhang X., Li D.Y., Xue H.Z., Pan C.E., Zhao S.H. Resveratrol inhibits VEGF expression of human hepatocellular carcinoma cells through a NF-kappa B-mediated mechanism. Hepatogastroenterology 2010, 57(102-103):1241-1246.
114. Bishayee A., Waghray A., Barnes K.F., Mbimba T., Bhatia D., Chatterjee M., Darvesh A.S. Suppression of the inflammatory cascade is implicated in resveratrol chemoprevention of experimental hepatocarcinogenesis. Pharm. Res. 2010, 27(6):1080-1091.
115. Tomic J., McCaw L., Li Y., Hough M.R., Ben-David Y., Moffat J., Spaner D.E. Resveratrol has anti-leukemic activity associated with decreased O-GlcNAcylated proteins. Exp. Hematol. 2013, 41(8):675-686.
116. Li T., Wang W., Chen H., Ye L. Evaluation of anti-leukemia effect of resveratrol by modulating STAT3 signaling. Int. Immunopharmacol. 2010, 10(1):18-25.
117. Berta G.N., Salamone P., Sprio A.E., Di Scipio F., Marinos L.M., Sapino S., Carlotti M.E., Cavalli R., Di Carlo F. Chemoprevention of 7,12-dimethylbenz[a]anthracene (DMBA)-induced oral carcinogenesis in hamster cheek pouch by topical application of resveratrol complexed with 2-hydroxypropyl-beta-cyclodextrin. Oral Oncol. 2010, 46(1):42-48.
118. Zhang M., Zhou X., Zhou K. Resveratrol inhibits human nasopharyngeal carcinoma cell growth via blocking pAkt/p70S6K signaling pathways. Int. J. Mol. Med. 2013, 31(3):621-627.
119. Hu F.W., Tsai L.L., Yu C.H., Chen P.N., Chou M.Y., Yu C.C. Impairment of tumor-initiating stem-like property and reversal of epithelial-mesenchymal transdifferentiation in head and neck cancer by resveratrol treatment. Mol. Nutr. Food Res. 2012, 56(8):1247-1258.
120. Tyagi A., Gu M., Takahata T., Frederick B., Agarwal C., Siriwardana S., Agarwal R., Sclafani R.A. Resveratrol selectively induces DNA Damage, independent of Smad4 expression, in its efficacy against human head and neck squamous cell carcinoma. Clin. Cancer Res. 2011, 17(16):5402-5411.
121. El-Azab M., Hishe H., Moustafa Y., El-Awady e.-S. Anti-angiogenic effect of resveratrol or curcumin in Ehrlich ascites carcinoma-bearing mice. Eur. J. Pharmacol. 2011, 652(1-3):7-14.
122. Wu M.L., Li H., Yu L.J., Chen X.Y., Kong Q.Y., Song X., Shu X.H., Liu J. Short-term resveratrol exposure causes in vitro and in vivo growth inhibition and apoptosis of bladder cancer cells. PLoS ONE 2014, 9(2):e89806.
123. Yang Q., Wang B., Zang W., Wang X., Liu Z., Li W., Jia J. Resveratrol inhibits the growth of gastric cancer by inducing G1 phase arrest and senescence in a Sirt1-dependent manner. PLoS ONE 2013, 8(11):e70627.
124. Roy S.K., Chen Q., Fu J., Shankar S., Srivastava R.K. Resveratrol inhibits growth of orthotopic pancreatic tumors through activation of FOXO transcription factors. PLoS ONE 2011, 6(9):e25166.
125. Stakleff K.S., Sloan T., Blanco D., Marcanthony S., Booth T.D., Bishayee A. Resveratrol exerts differential effects in vitro and in vivo against ovarian cancer cells. Asian Pac. J. Cancer Prev. 2012, 13(4):1333-1340.
126. Salado C., Olaso E., Gallot N., Valcarcel M., Egilegor E., Mendoza L., Vidal-Vanaclocha F. Resveratrol prevents inflammation-dependent hepatic melanoma metastasis by inhibiting the secretion and effects of interleukin-18. J. Transl. Med. 2011, 9:59.
127. Lee H.S., Ha A.W., Kim W.K. Effect of resveratrol on the metastasis of 4T1 mouse breast cancer cells in vitro and in vivo. Nutr. Res. Pract. 2012, 6(4):294-300.
128. Chen M.C., Chang W.W., Kuan Y.D., Lin S.T., Hsu H.C., Lee C.H. Resveratrol inhibits LPS-induced epithelial-mesenchymal transition in mouse melanoma model. Innate Immun. 2012, 18(5):685-693.
129. Sha H., Ma Q., Jha R.K., Wu Z., Qingyuan Z., Wang Z., Ma Z., Luo X., Liu C. Resveratrol suppresses microcirculatory disturbance in a rat model of severe acute pancreatitis. Cell Biochem. Biophys. 2013, 67(3):1059-1065.
130. Jha R.K., Ma Q., Lei Z., Sha H. Resveratrol ameliorates the deleterious effect of severe acute pancreatitis. Cell Biochem. Biophys. 2012, 62(2):397-402.
131. Rahal K., Schmiedlin-Ren P., Adler J., Dhanani M., Sultani V., Rittershaus A.C., Reingold L., Zhu J., McKenna B.J., Christman G.M., et al. Resveratrol has antiinflammatory and antifibrotic effects in the peptidoglycan-polysaccharide rat model of Crohn's disease. Inflamm. Bowel Dis. 2012, 18(4):613-623.
132. Wang J., Gao J.S., Chen J.W., Li F., Tian J. Effect of resveratrol on cartilage protection and apoptosis inhibition in experimental osteoarthritis of rabbit. Rheumatol. Int. 2012, 32(6):1541-1548.
133. Bereswill S., Muñoz M., Fischer A., Plickert R., Haag L.M., Otto B., Kühl A.A., Loddenkemper C., Göbel U.B., Heimesaat M.M. Anti-inflammatory effects of resveratrol, curcumin and simvastatin in acute small intestinal inflammation. PLoS ONE 2010, 5(12):e15099.
134. Sánchez-Fidalgo S., Cárdeno A., Villegas I., Talero E., de la Lastra C.A. Dietary supplementation of resveratrol attenuates chronic colonic inflammation in mice. Eur. J. Pharmacol. 2010, 633(1-3):78-84.
135. Issuree P.D., Pushparaj P.N., Pervaiz S., Melendez A.J. Resveratrol attenuates C5a-induced inflammatory responses in vitro and in vivo by inhibiting phospholipase D and sphingosine kinase activities. FASEB J. 2009, 23(8):2412-2424.
136. Van der Wal S.E., Vaneker M., Kox M., Braak G., Van Hees H.W., Van den Brink I.A., Van de Pol F.M., Heunks L.M., Van der Hoeven J.G., Joosten L.A., et al. Resveratrol attenuates NF-κB-binding activity but not cytokine production in mechanically ventilated mice. Acta Anaesthesiol. Scand. 2014, 58(4):487-494.
137. + T cell activation by enhancing the expression and activity of Sirt1. PLoS ONE 2013, 8(9):e75139.
138. Elmadhun N.Y., Sabe A.A., Robich M.P., Chu L.M., Lassaletta A.D., Sellke F.W. The pig as a valuable model for testing the effect of resveratrol to prevent cardiovascular disease. Ann. N. Y. Acad. Sci. 2013, 1290:130-135.
139. Bendixen E., Danielsen M., Larsen K., Bendixen C. Advances in porcine genomics and proteomics-a toolbox for developing the pig as a model organism for molecular biomedical research. Brief. Funct. Genomics 2010, 9(3):208-219.
140. Zou J., Huang Y., Cao K., Yang G., Yin H., Len J., Hsieh T.C., Wu J.M. Effect of resveratrol on intimal hyperplasia after endothelial denudation in an experimental rabbit model. Life Sci. 2000, 68(2):153-163.
141. Gu J., Wang C., Zhang D., Fan H., He B., Wang B., Huang D. Effects of resveratrol on reendothelialization and neointimal formation in intimal injury model. Zhongguo Dongmai Yinghua Zazhi 2006, 14(10):829-834.
142. Khandelwal A.R., Hebert V.Y., Dugas T.R. Essential role of ER-alpha-dependent NO production in resveratrol-mediated inhibition of restenosis. Am. J. Physiol. Heart Circ. Physiol. 2010, 299(5):H1451-H1458.
143. Breen D.M., Dolinsky V.W., Zhang H., Ghanim H., Guo J., Mroziewicz M., Tsiani E.L., Bendeck M.P., Dandona P., Dyck J.R., et al. Resveratrol inhibits neointimal formation after arterial injury through an endothelial nitric oxide synthase-dependent mechanism. Atherosclerosis 2012, 222(2):375-381.
144. Zhang J., Chen J., Yang J., Xu C.W., Pu P., Ding J.W., Jiang H. Resveratrol attenuates oxidative stress induced by balloon injury in the rat carotid artery through actions on the ERK1/2 and NF-kappa B pathway. Cell. Physiol. Biochem. 2013, 31(2-3):230-241.
145. Mizutani K., Ikeda K., Kawai Y., Yamori Y. Resveratrol attenuates ovariectomy-induced hypertension and bone loss in stroke-prone spontaneously hypertensive rats. J. Nutr. Sci. Vitaminol. (Tokyo) 2000, 46(2):78-83.
146. Mizutani K., Ikeda K., Kawai Y., Yamori Y. Protective effect of resveratrol on oxidative damage in male and female stroke-prone spontaneously hypertensive rats. Clin. Exp. Pharmacol. Physiol. 2001, 28(1-2):55-59.
147. Rush J.W., Quadrilatero J., Levy A.S., Ford R.J. Chronic resveratrol enhances endothelium-dependent relaxation but does not alter eNOS levels in aorta of spontaneously hypertensive rats. Exp. Biol. Med. (Maywood) 2007, 232(6):814-822.
148. Dolinsky V.W., Chan A.Y., Robillard Frayne I., Light P.E., Des Rosiers C., Dyck J.R. Resveratrol prevents the prohypertrophic effects of oxidative stress on LKB1. Circulation 2009, 119(12):1643-1652.
149. Thandapilly S.J., Wojciechowski P., Behbahani J., Louis X.L., Yu L., Juric D., Kopilas M.A., Anderson H.D., Netticadan T. Resveratrol prevents the development of pathological cardiac hypertrophy and contractile dysfunction in the SHR without lowering blood pressure. Am. J. Hypertens. 2010, 23(2):192-196.
150. Behbahani J., Thandapilly S.J., Louis X.L., Huang Y., Shao Z., Kopilas M.A., Wojciechowski P., Netticadan T., Anderson H.D. Resveratrol and small artery compliance and remodeling in the spontaneously hypertensive rat. Am. J. Hypertens. 2010, 23(12):1273-1278.
151. Dolinsky V.W., Chakrabarti S., Pereira T.J., Oka T., Levasseur J., Beker D., Zordoky B.N., Morton J.S., Nagendran J., Lopaschuk G.D., et al. Resveratrol prevents hypertension and cardiac hypertrophy in hypertensive rats and mice. Biochim. Biophys. Acta 2013, 1832(10):1723-1733.
152. Thandapilly S.J., Louis X.L., Behbahani J., Movahed A., Yu L., Fandrich R., Zhang S., Kardami E., Anderson H.D., Netticadan T. Reduced hemodynamic load aids low-dose resveratrol in reversing cardiovascular defects in hypertensive rats. Hypertens. Res. 2013, 36(10):866-872.
153. Paffett M.L., Lucas S.N., Campen M.J. Resveratrol reverses monocrotaline-induced pulmonary vascular and cardiac dysfunction: a potential role for atrogin-1 in smooth muscle. Vasc. Pharmacol. 2012, 56(1-2):64-73.
154. Rimbaud S., Ruiz M., Piquereau J., Mateo P., Fortin D., Veksler V., Garnier A., Ventura-Clapier R. Resveratrol improves survival, hemodynamics and energetics in a rat model of hypertension leading to heart failure. PLoS ONE 2011, 6(10):e26391.
155. Subramanian M., Balasubramanian P., Garver H., Northcott C., Zhao H., Haywood J.R., Fink G.D., MohanKumar S.M., MohanKumar P.S. Chronic estradiol-17β exposure increases superoxide production in the rostral ventrolateral medulla and causes hypertension: reversal by resveratrol. Am. J. Physiol. Regul. Integr. Comp. Physiol. 2011, 300(6):R1560-R1568.
156. Moraloglu O., Engin-Ustun Y., Tonguç E., Var T., Tapisiz O.L., Ergün H., Guvenc T., Gacar A. The effect of resveratrol on blood pressure in a rat model of preeclampsia. J. Matern. Fetal Neonatal Med. 2012, 25(6):845-848.
157. Cheng P.W., Ho W.Y., Su Y.T., Lu P.J., Chen B.Z., Cheng W.H., Lu W.H., Sun G.C., Yeh T.C., Hsiao M., et al. Resveratrol decreases fructose-induced oxidative stress, mediated by NADPH oxidase via an AMPK-dependent mechanism. Br. J. Pharmacol. 2014, 171(11):2739-2750.
158. Xuan W., Wu B., Chen C., Chen B., Zhang W., Xu D., Bin J., Liao Y. Resveratrol improves myocardial ischemia and ischemic heart failure in mice by antagonizing the detrimental effects of fractalkine*. Crit. Care Med. 2012, 40(11):3026-3033.
159. Lin J.F., Wu S., Huang S.S., Lu B.Y., Lin S.M., Tsai S.K. Resveratrol protects left ventricle by increasing adenylate kinase and isocitrate dehydrogenase activities in rats with myocardial infarction. Chin. J. Physiol. 2011, 54(6):406-412.
160. Naumenko S.E., Latysheva T.V., Gilinsky M.A., Rogachev A.D., Komarova N.I., Salakhutdinov N.F., Tolstikov G.A. Cardioprotective effect of resveratrol and resveratroloside. Cardiovasc. Hematol. Agents Med. Chem. 2013, 11(3):207-210.
161. Mokni M., Hamlaoui S., Karkouch I., Amri M., Marzouki L., Limam F., Aouani E. Resveratrol provides cardioprotection after ischemia/reperfusion injury via modulation of antioxidant enzyme activities. Iran J. Pharm. Res. 2013, 12(4):867-875.
162. Sabe A.A., Elmadhun N.Y., Dalal R.S., Robich M.P., Sellke F.W. Resveratrol regulates autophagy signaling in chronically ischemic myocardium. J. Thorac. Cardiovasc. Surg. 2014, 147(2):792-798. (Discussion 798-799).
163. Sabe A.A., Elmadhun N.Y., Robich M.P., Dalal R.S., Sellke F.W. Does resveratrol improve insulin signaling in chronically ischemic myocardium?. J. Surg. Res. 2013, 183(2):531-536.
164. Robich M.P., Osipov R.M., Nezafat R., Feng J., Clements R.T., Bianchi C., Boodhwani M., Coady M.A., Laham R.J., Sellke F.W. Resveratrol improves myocardial perfusion in a swine model of hypercholesterolemia and chronic myocardial ischemia. Circulation 2010, 122(11 Suppl.):S142-S149.
165. Robich M.P., Osipov R.M., Chu L.M., Han Y., Feng J., Nezafat R., Clements R.T., Manning W.J., Sellke F.W. Resveratrol modifies risk factors for coronary artery disease in swine with metabolic syndrome and myocardial ischemia. Eur. J. Pharmacol. 2011, 664(1-3):45-53.
166. Matos R.S., Baroncini L.A., Précoma L.B., Winter G., Lambach P.H., Caron E.Y., Kaiber F., Précoma D.B. Resveratrol causes antiatherogenic effects in an animal model of atherosclerosis. Arq. Bras. Cardiol. 2012, 98(2):136-142.
167. Berbée J.F., Wong M.C., Wang Y., van der Hoorn J.W., Khedoe P.P., van Klinken J.B., Mol I.M., Hiemstra P.S., Tsikas D., Romijn J.A., et al. Resveratrol protects against atherosclerosis, but does not add to the antiatherogenic effect of atorvastatin, in APOE*3-Leiden.CETP mice. J. Nutr. Biochem. 2013, 24(8):1423-1430.
168. Azorín-Ortuño M., Yáñez-Gascón M.J., González-Sarrías A., Larrosa M., Vallejo F., Pallarés F.J., Lucas R., Morales J.C., Tomás-Barberán F.A., García-Conesa M.T., et al. Effects of long-term consumption of low doses of resveratrol on diet-induced mild hypercholesterolemia in pigs: a transcriptomic approach to disease prevention. J. Nutr. Biochem. 2012, 23(7):829-837.
169. Azorín-Ortuño M., Yañéz-Gascón M.J., Pallarés F.J., Rivera J., González-Sarrías A., Larrosa M., Vallejo F., García-Conesa M.T., Tomás-Barberán F., Espín J.C. A dietary resveratrol-rich grape extract prevents the developing of atherosclerotic lesions in the aorta of pigs fed an atherogenic diet. J. Agric. Food Chem. 2012, 60(22):5609-5620.
170. Hao E., Lang F., Chen Y., Zhang H., Cong X., Shen X., Su G. Resveratrol alleviates endotoxin-induced myocardial toxicity via the Nrf2 transcription factor. PLoS ONE 2013, 8(7):e69452.
171. Dolinsky V.W., Rogan K.J., Sung M.M., Zordoky B.N., Haykowsky M.J., Young M.E., Jones L.W., Dyck J.R. Both aerobic exercise and resveratrol supplementation attenuate doxorubicin-induced cardiac injury in mice. Am. J. Physiol. Endocrinol. Metab. 2013, 305(2):E243-E253.
172. Arafa M.H., Mohammad N.S., Atteia H.H., Abd-Elaziz H.R. Protective effect of resveratrol against doxorubicin-induced cardiac toxicity and fibrosis in male experimental rats. J. Physiol. Biochem. 2014, 70(3):701-711.
173. Wojciechowski P., Juric D., Louis X.L., Thandapilly S.J., Yu L., Taylor C., Netticadan T. Resveratrol arrests and regresses the development of pressure overload- but not volume overload-induced cardiac hypertrophy in rats. J. Nutr. 2010, 140(5):962-968.
174. Tsai Y.F., Liu F.C., Lau Y.T., Yu H.P. Role of Akt-dependent pathway in resveratrol-mediated cardioprotection after trauma-hemorrhage. J. Surg. Res. 2012, 176(1):171-177.
175. Rius C., Abu-Taha M., Hermenegildo C., Piqueras L., Cerda-Nicolas J.M., Issekutz A.C., Estañ L., Cortijo J., Morcillo E.J., Orallo F., et al. Trans- but not cis-resveratrol impairs angiotensin-II-mediated vascular inflammation through inhibition of NF-κB activation and peroxisome proliferator-activated receptor-gamma upregulation. J. Immunol. 2010, 185(6):3718-3727.
176. Kaneko H., Anzai T., Morisawa M., Kohno T., Nagai T., Anzai A., Takahashi T., Shimoda M., Sasaki A., Maekawa Y., et al. Resveratrol prevents the development of abdominal aortic aneurysm through attenuation of inflammation, oxidative stress, and neovascularization. Atherosclerosis 2011, 217(2):350-357.
177. Palmieri D., Pane B., Barisione C., Spinella G., Garibaldi S., Ghigliotti G., Brunelli C., Fulcheri E., Palombo D. Resveratrol counteracts systemic and local inflammation involved in early abdominal aortic aneurysm development. J. Surg. Res. 2011, 171(2):e237-e246.
178. Ungvari Z., Bagi Z., Feher A., Recchia F.A., Sonntag W.E., Pearson K., de Cabo R., Csiszar A. Resveratrol confers endothelial protection via activation of the antioxidant transcription factor Nrf2. Am. J. Physiol. Heart Circ. Physiol. 2010, 299(1):H18-H24.
179. Gordish K.L., Beierwaltes W.H. Resveratrol induces acute endothelium-dependent renal vasodilation mediated through nitric oxide and reactive oxygen species scavenging. Am. J. Physiol. Renal Physiol. 2014, 306(5):F542-F550.
180. Yurdagul A., Kleinedler J.J., McInnis M.C., Khandelwal A.R., Spence A.L., Orr A.W., Dugas T.R. Resveratrol promotes endothelial cell wound healing under laminar shear stress through an estrogen receptor-α-dependent pathway. Am. J. Physiol. Heart Circ. Physiol. 2014, 306(6):H797-H806.
181. Wang N., Ko S.H., Chai W., Li G., Barrett E.J., Tao L., Cao W., Liu Z. Resveratrol recruits rat muscle microvasculature via a nitric oxide-dependent mechanism that is blocked by TNFα. Am. J. Physiol. Endocrinol. Metab. 2011, 300(1):E195-E201.
182. Arcand S., Sharma K., Al-Dissi A.N., Cadete V.J., Sawicki G., Weber L.P. Resveratrol protects against functional impairment and cardiac structural protein degradation induced by secondhand smoke exposure. Can. J. Cardiol. 2013, 29(10):1320-1328.
183. Lee J.H., Yang S.H., Oh J.M., Lee M.G. Pharmacokinetics of drugs in rats with diabetes mellitus induced by alloxan or streptozocin: comparison with those in patients with type I diabetes mellitus. J. Pharm. Pharmacol. 2010, 62(1):1-23.
184. Rochette L., Zeller M., Cottin Y., Vergely C. Diabetes, oxidative stress and therapeutic strategies. Biochim. Biophys. Acta 2014, 1840(9):2709-2729.
185. Chen W.P., Chi T.C., Chuang L.M., Su M.J. Resveratrol enhances insulin secretion by blocking K(ATP) and K(V) channels of beta cells. Eur. J. Pharmacol. 2007, 568(1-3):269-277.
186. Tikoo K., Singh K., Kabra D., Sharma V., Gaikwad A. Change in histone H3 phosphorylation, MAP kinase p38, SIR 2 and p53 expression by resveratrol in preventing streptozotocin induced type I diabetic nephropathy. Free Radic. Res. 2008, 42(4):397-404.
187. Su H.C., Hung L.M., Chen J.K. Resveratrol, a red wine antioxidant, possesses an insulin-like effect in streptozotocin-induced diabetic rats. Am. J. Physiol. Endocrinol. Metab. 2006, 290(6):E1339-E1346.
188. Chi T.C., Chen W.P., Chi T.L., Kuo T.F., Lee S.S., Cheng J.T., Su M.J. Phosphatidylinositol-3-kinase is involved in the antihyperglycemic effect induced by resveratrol in streptozotocin-induced diabetic rats. Life Sci. 2007, 80(18):1713-1720.
189. Thirunavukkarasu M., Penumathsa S.V., Koneru S., Juhasz B., Zhan L., Otani H., Bagchi D., Das D.K., Maulik N. Resveratrol alleviates cardiac dysfunction in streptozotocin-induced diabetes: role of nitric oxide, thioredoxin, and heme oxygenase. Free Radic. Biol. Med. 2007, 43(5):720-729.
190. Silan C. The effects of chronic resveratrol treatment on vascular responsiveness of streptozotocin-induced diabetic rats. Biol. Pharm. Bull. 2008, 31(5):897-902.
191. Palsamy P., Subramanian S. Resveratrol, a natural phytoalexin, normalizes hyperglycemia in streptozotocin-nicotinamide induced experimental diabetic rats. Biomed. Pharmacother. 2008, 62(9):598-605.
192. Penumathsa S.V., Thirunavukkarasu M., Zhan L., Maulik G., Menon V.P., Bagchi D., Maulik N. Resveratrol enhances GLUT-4 translocation to the caveolar lipid raft fractions through AMPK/Akt/eNOS signalling pathway in diabetic myocardium. J. Cell. Mol. Med. 2008, 12(6A):2350-2361.
193. Ates O., Cayli S.R., Yucel N., Altinoz E., Kocak A., Durak M.A., Turkoz Y., Yologlu S. Central nervous system protection by resveratrol in streptozotocin-induced diabetic rats. J. Clin. Neurosci. 2007, 14(3):256-260.
194. Kumar A., Kaundal R.K., Iyer S., Sharma S.S. Effects of resveratrol on nerve functions, oxidative stress and DNA fragmentation in experimental diabetic neuropathy. Life Sci. 2007, 80(13):1236-1244.
195. Aribal-Kocatürk P., Kavas G.O., Büyükkağnici D.I. Pretreatment effect of resveratrol on streptozotocin-induced diabetes in rats. Biol. Trace Elem. Res. 2007, 118(3):244-249.
196. Sharma S., Kulkarni S.K., Chopra K. Resveratrol, a polyphenolic phytoalexin attenuates thermal hyperalgesia and cold allodynia in STZ-induced diabetic rats. Indian J. Exp. Biol. 2006, 44(7):566-569.
197. Sharma S., Kulkarni S.K., Chopra K. Effect of resveratrol, a polyphenolic phytoalexin, on thermal hyperalgesia in a mouse model of diabetic neuropathic pain. Fundam. Clin. Pharmacol. 2007, 21(1):89-94.
198. Schmatz R., Mazzanti C.M., Spanevello R., Stefanello N., Gutierres J., Maldonado P.A., Corrêa M., da Rosa C.S., Becker L., Bagatini M., et al. Ectonucleotidase and acetylcholinesterase activities in synaptosomes from the cerebral cortex of streptozotocin-induced diabetic rats and treated with resveratrol. Brain Res. Bull. 2009, 80(6):371-376.
199. Schmatz R., Mazzanti C.M., Spanevello R., Stefanello N., Gutierres J., Corrêa M., da Rosa M.M., Rubin M.A., Chitolina Schetinger M.R., Morsch V.M. Resveratrol prevents memory deficits and the increase in acetylcholinesterase activity in streptozotocin-induced diabetic rats. Eur. J. Pharmacol. 2009, 610(1-3):42-48.
200. Palsamy P., Subramanian S. Resveratrol protects diabetic kidney by attenuating hyperglycemia-mediated oxidative stress and renal inflammatory cytokines via Nrf2-Keap1 signaling. Biochim. Biophys. Acta 2011, 1812(7):719-731.
201. Palsamy P., Sivakumar S., Subramanian S. Resveratrol attenuates hyperglycemia-mediated oxidative stress, proinflammatory cytokines and protects hepatocytes ultrastructure in streptozotocin-nicotinamide-induced experimental diabetic rats. Chem. Biol. Interact. 2010, 186(2):200-210.
202. Soufi F.G., Sheervalilou R., Vardiani M., Khalili M., Alipour M.R. Chronic resveratrol administration has beneficial effects in experimental model of type 2 diabetic rats. Endocr. Regul. 2012, 46(2):83-90.
203. Chang C.C., Chang C.Y., Wu Y.T., Huang J.P., Yen T.H., Hung L.M. Resveratrol retards progression of diabetic nephropathy through modulations of oxidative stress, proinflammatory cytokines, and AMP-activated protein kinase. J. Biomed. Sci. 2011, 18(1):47.
204. Jing Y.H., Chen K.H., Kuo P.C., Pao C.C., Chen J.K. Neurodegeneration in streptozotocin-induced diabetic rats is attenuated by treatment with resveratrol. Neuroendocrinology 2013, 98(2):116-127.
205. Chen K.H., Cheng M.L., Jing Y.H., Chiu D.T., Shiao M.S., Chen J.K. Resveratrol ameliorates metabolic disorders and muscle wasting in streptozotocin-induced diabetic rats. Am. J. Physiol. Endocrinol. Metab. 2011, 301(5):E853-E863.
206. Schmatz R., Perreira L.B., Stefanello N., Mazzanti C., Spanevello R., Gutierres J., Bagatini M., Martins C.C., Abdalla F.H., Daci da Silva Serres J., et al. Effects of resveratrol on biomarkers of oxidative stress and on the activity of delta aminolevulinic acid dehydratase in liver and kidney of streptozotocin-induced diabetic rats. Biochimie 2012, 94(2):374-383.
207. Hamadi N., Mansour A., Hassan M.H., Khalifi-Touhami F., Badary O. Ameliorative effects of resveratrol on liver injury in streptozotocin-induced diabetic rats. J. Biochem. Mol. Toxicol. 2012, 26(10):384-392.
208. Xu F., Wang Y., Cui W., Yuan H., Sun J., Wu M., Guo Q., Kong L., Wu H., Miao L. Resveratrol prevention of diabetic nephropathy is associated with the suppression of renal inflammation and mesangial cell proliferation: possible roles of Akt/NF-κB pathway. Int. J. Endocrinol. 2014, 2014:289327.
209. Huang J.P., Huang S.S., Deng J.Y., Chang C.C., Day Y.J., Hung L.M. Insulin and resveratrol act synergistically, preventing cardiac dysfunction in diabetes, but the advantage of resveratrol in diabetics with acute heart attack is antagonized by insulin. Free Radic. Biol. Med. 2010, 49(11):1710-1721.
210. Prabhakar O. Cerebroprotective effect of resveratrol through antioxidant and anti-inflammatory effects in diabetic rats. Naunyn Schmiedeberg's Arch. Pharmacol. 2013, 386(8):705-710.
211. Palsamy P., Subramanian S. Ameliorative potential of resveratrol on proinflammatory cytokines, hyperglycemia mediated oxidative stress, and pancreatic beta-cell dysfunction in streptozotocin-nicotinamide-induced diabetic rats. J. Cell. Physiol. 2010, 224(2):423-432.
212. Carolo Dos Santos K., Pereira Braga C., Octavio Barbanera P., Rodrigues Ferreira Seiva F., Fernandes Junior A., Fernandes A.A. Cardiac energy metabolism and oxidative stress biomarkers in diabetic rat treated with resveratrol. PLoS ONE 2014, 9(7):e102775.
213. Chen K.H., Hung C.C., Hsu H.H., Jing Y.H., Yang C.W., Chen J.K. Resveratrol ameliorates early diabetic nephropathy associated with suppression of augmented TGF-β/smad and ERK1/2 signaling in streptozotocin-induced diabetic rats. Chem. Biol. Interact. 2011, 190(1):45-53.
214. Wu L., Zhang Y., Ma X., Zhang N., Qin G. The effect of resveratrol on FoxO1 expression in kidneys of diabetic nephropathy rats. Mol. Biol. Rep. 2012, 39(9):9085-9093.
215. Yar A.S., Menevse S., Alp E. The effects of resveratrol on cyclooxygenase-1 and -2, nuclear factor kappa beta, matrix metalloproteinase-9, and sirtuin 1 mRNA expression in hearts of streptozotocin-induced diabetic rats. Genet. Mol. Res. 2011, 10(4):2962-2975.
216. Yar A.S., Menevse S., Alp E., Helvacioglu F., Take G. The effects of resveratrol on cyclooxygenase-1 and cyclooxygenase-2 mRNA and protein levels in diabetic rat kidneys. Mol. Biol. Rep. 2010, 37(5):2323-2331.
217. Jing Y.H., Chen K.H., Yang S.H., Kuo P.C., Chen J.K. Resveratrol ameliorates vasculopathy in STZ-induced diabetic rats: role of AGE-RAGE signalling. Diabetes Metab. Res. Rev. 2010, 26(3):212-222.
218. Yu W., Wan Z., Qiu X.F., Chen Y., Dai Y.T. Resveratrol, an activator of SIRT1, restores erectile function in streptozotocin-induced diabetic rats. Asian J. Androl. 2013, 15(5):646-651.
219. Palsamy P., Subramanian S. Modulatory effects of resveratrol on attenuating the key enzymes activities of carbohydrate metabolism in streptozotocin-nicotinamide-induced diabetic rats. Chem. Biol. Interact. 2009, 179(2-3):356-362.
220. Zheng X., Zhu S., Chang S., Cao Y., Dong J., Li J., Long R., Zhou Y. Protective effects of chronic resveratrol treatment on vascular inflammatory injury in streptozotocin-induced type 2 diabetic rats: role of NF-kappa B signaling. Eur. J. Pharmacol. 2013, 720(1-3):147-157.
221. Chang C.C., Chang C.Y., Huang J.P., Hung L.M. Effect of resveratrol on oxidative and inflammatory stress in liver and spleen of streptozotocin-induced type 1 diabetic rats. Chin. J. Physiol. 2012, 55(3):192-201.
222. Soufi F.G., Vardyani M., Sheervalilou R., Mohammadi M., Somi M.H. Long-term treatment with resveratrol attenuates oxidative stress pro-inflammatory mediators and apoptosis in streptozotocin-nicotinamide-induced diabetic rats. Gen. Physiol. Biophys. 2012, 31(4):431-438.
223. Arrick D.M., Sun H., Patel K.P., Mayhan W.G. Chronic resveratrol treatment restores vascular responsiveness of cerebral arterioles in type 1 diabetic rats. Am. J. Physiol. Heart Circ. Physiol. 2011, 301(3):H696-H703.
224. Wang B., Yang Q., Sun Y.Y., Xing Y.F., Wang Y.B., Lu X.T., Bai W.W., Liu X.Q., Zhao Y.X. Resveratrol-enhanced autophagic flux ameliorates myocardial oxidative stress injury in diabetic mice. J. Cell. Mol. Med. 2014, 18(8):1599-1611.
225. Sulaiman M., Matta M.J., Sunderesan N.R., Gupta M.P., Periasamy M., Gupta M. Resveratrol, an activator of SIRT1, upregulates sarcoplasmic calcium ATPase and improves cardiac function in diabetic cardiomyopathy. Am. J. Physiol. Heart Circ. Physiol. 2010, 298(3):H833-H843.
226. Roghani M., Baluchnejadmojarad T. Mechanisms underlying vascular effect of chronic resveratrol in streptozotocin-diabetic rats. Phytother. Res. 2010, 24(Suppl. 2):S148-S154.
227. Sharma S., Anjaneyulu M., Kulkarni S.K., Chopra K. Resveratrol, a polyphenolic phytoalexin, attenuates diabetic nephropathy in rats. Pharmacology 2006, 76(2):69-75.
228. Jiang B., Guo L., Li B.Y., Zhen J.H., Song J., Peng T., Yang X.D., Hu Z., Gao H.Q. Resveratrol attenuates early diabetic nephropathy by down-regulating glutathione s-transferases Mu in diabetic rats. J. Med. Food 2013, 16(6):481-486.
229. Mohamad Shahi M., Haidari F., Shiri M.R. Comparison of effect of resveratrol and vanadium on diabetes related dyslipidemia and hyperglycemia in streptozotocin induced diabetic rats. Adv. Pharm. Bull. 2011, 1(2):81-86.
230. Delucchi F., Berni R., Frati C., Cavalli S., Graiani G., Sala R., Chaponnier C., Gabbiani G., Calani L., Del Rio D., et al. Resveratrol treatment reduces cardiac progenitor cell dysfunction and prevents morpho-functional ventricular remodeling in type-1 diabetic rats. PLoS ONE 2012, 7(6):e39836.
231. Roy Chowdhury S.K., Smith D.R., Saleh A., Schapansky J., Marquez A., Gomes S., Akude E., Morrow D., Calcutt N.A., Fernyhough P. Impaired adenosine monophosphate-activated protein kinase signalling in dorsal root ganglia neurons is linked to mitochondrial dysfunction and peripheral neuropathy in diabetes. Brain 2012, 135(Pt 6):1751-1766.
232. Damián J.P., Acosta V., Da Cuña M., Ramírez I., Oddone N., Zambrana A., Bervejillo V., Benech J.C. Effect of resveratrol on behavioral performance of streptozotocin-induced diabetic mice in anxiety tests. Exp. Anim. 2014, 63(3):277-287.
233. Thomas J., Garg M.L., Smith D.W. Dietary resveratrol supplementation normalizes gene expression in the hippocampus of streptozotocin-induced diabetic C57Bl/6 mice. J. Nutr. Biochem. 2014, 25(3):313-318.
234. McCall M.D., Pawlick R., Shapiro A.M. Resveratrol fails to improve marginal mass engraftment of transplanted islets of Langerhans in mice. Islets 2011, 3(5):241-245.
235. Ku C.R., Lee H.J., Kim S.K., Lee E.Y., Lee M.K., Lee E.J. Resveratrol prevents streptozotocin-induced diabetes by inhibiting the apoptosis of pancreatic β-cell and the cleavage of poly (ADP-ribose) polymerase. Endocr. J. 2012, 59(2):103-109.
236. Fukuhara S., Tsujimura A., Okuda H., Yamamoto K., Takao T., Miyagawa Y., Nonomura N., Okuyama A. Vardenafil and resveratrol synergistically enhance the nitric oxide/cyclic guanosine monophosphate pathway in corpus cavernosal smooth muscle cells and its therapeutic potential for erectile dysfunction in the streptozotocin-induced diabetic rat: preliminary findings. J. Sex. Med. 2011, 8(4):1061-1071.
237. Chang C.C., Yang M.H., Tung H.C., Chang C.Y., Tsai Y.L., Huang J.P., Yen T.H., Hung L.M. Resveratrol exhibits differential protective effects on fast- and slow-twitch muscles in streptozotocin-induced diabetic rats. J. Diabetes 2014, 6(1):60-67.
238. Zeytin K., Ciloğlu N.S., Ateş F., Vardar Aker F., Ercan F. The effects of resveratrol on tendon healing of diabetic rats. Acta Orthop. Traumatol. Turc. 2014, 48(3):355-362.
239. Singh C.K., Kumar A., LaVoie H.A., DiPette D.J., Singh U.S. Resveratrol prevents impairment in activation of retinoic acid receptors and MAP kinases in the embryos of a rodent model of diabetic embryopathy. Reprod. Sci. 2012, 19(9):949-961.
240. Jeon B.T., Jeong E.A., Shin H.J., Lee Y., Lee D.H., Kim H.J., Kang S.S., Cho G.J., Choi W.S., Roh G.S. Resveratrol attenuates obesity-associated peripheral and central inflammation and improves memory deficit in mice fed a high-fat diet. Diabetes 2012, 61(6):1444-1454.
241. Kang W., Hong H.J., Guan J., Kim D.G., Yang E.J., Koh G., Park D., Han C.H., Lee Y.J., Lee D.H. Resveratrol improves insulin signaling in a tissue-specific manner under insulin-resistant conditions only: in vitro and in vivo experiments in rodents. Metabolism 2012, 61(3):424-433.
242. Qiao Y., Sun J., Xia S., Tang X., Shi Y., Le G. Effects of resveratrol on gut microbiota and fat storage in a mouse model with high-fat-induced obesity. Food Funct. 2014, 5(6):1241-1249.
243. Zhang J., Chen L., Zheng J., Zeng T., Li H., Xiao H., Deng X., Hu X. The protective effect of resveratrol on islet insulin secretion and morphology in mice on a high-fat diet. Diabetes Res. Clin. Pract. 2012, 97(3):474-482.
244. Ramadori G., Gautron L., Fujikawa T., Vianna C.R., Elmquist J.K., Coppari R. Central administration of resveratrol improves diet-induced diabetes. Endocrinology 2009, 150(12):5326-5333.
245. Um J.H., Park S.J., Kang H., Yang S., Foretz M., McBurney M.W., Kim M.K., Viollet B., Chung J.H. AMP-activated protein kinase-deficient mice are resistant to the metabolic effects of resveratrol. Diabetes 2010, 59(3):554-563.
246. Dao T.M., Waget A., Klopp P., Serino M., Vachoux C., Pechere L., Drucker D.J., Champion S., Barthélemy S., Barra Y., et al. Resveratrol increases glucose induced GLP-1 secretion in mice: a mechanism which contributes to the glycemic control. PLoS ONE 2011, 6(6):e20700.
247. Macarulla M.T., Alberdi G., Gómez S., Tueros I., Bald C., Rodríguez V.M., Martínez J.A., Portillo M.P. Effects of different doses of resveratrol on body fat and serum parameters in rats fed a hypercaloric diet. J. Physiol. Biochem. 2009, 65(4):369-376.
248. Jimenez-Gomez Y., Mattison J.A., Pearson K.J., Martin-Montalvo A., Palacios H.H., Sossong A.M., Ward T.M., Younts C.M., Lewis K., Allard J.S., et al. Resveratrol improves adipose insulin signaling and reduces the inflammatory response in adipose tissue of rhesus monkeys on high-fat, high-sugar diet. Cell Metab. 2013, 18(4):533-545.
249. Fiori J.L., Shin Y.K., Kim W., Krzysik-Walker S.M., González-Mariscal I., Carlson O.D., Sanghvi M., Moaddel R., Farhang K., Gadkaree S.K., et al. Resveratrol prevents β-cell dedifferentiation in nonhuman primates given a high-fat/high-sugar diet. Diabetes 2013, 62(10):3500-3513.
250. Burgess T.A., Robich M.P., Chu L.M., Bianchi C., Sellke F.W. Improving glucose metabolism with resveratrol in a swine model of metabolic syndrome through alteration of signaling pathways in the liver and skeletal muscle. Arch. Surg. 2011, 146(5):556-564.
251. Robich M.P., Chu L.M., Chaudray M., Nezafat R., Han Y., Clements R.T., Laham R.J., Manning W.J., Coady M.A., Sellke F.W. Anti-angiogenic effect of high-dose resveratrol in a swine model of metabolic syndrome. Surgery 2010, 148(2):453-462.
252. Virgili M., Contestabile A. Partial neuroprotection of in vivo excitotoxic brain damage by chronic administration of the red wine antioxidant agent, trans-resveratrol in rats. Neurosci. Lett. 2000, 281(2-3):123-126.
253. Gupta Y.K., Briyal S., Chaudhary G. Protective effect of trans-resveratrol against kainic acid-induced seizures and oxidative stress in rats. Pharmacol. Biochem. Behav. 2002, 71(1-2):245-249.
254. Wang Q., Yu S., Simonyi A., Rottinghaus G., Sun G.Y., Sun A.Y. Resveratrol protects against neurotoxicity induced by kainic acid. Neurochem. Res. 2004, 29(11):2105-2112.
255. Huang S.S., Tsai M.C., Chih C.L., Hung L.M., Tsai S.K. Resveratrol reduction of infarct size in Long-Evans rats subjected to focal cerebral ischemia. Life Sci. 2001, 69(9):1057-1065.
256. Sinha K., Chaudhary G., Gupta Y.K. Protective effect of resveratrol against oxidative stress in middle cerebral artery occlusion model of stroke in rats. Life Sci. 2002, 71(6):655-665.
257. Inoue H., Jiang X.F., Katayama T., Osada S., Umesono K., Namura S. Brain protection by resveratrol and fenofibrate against stroke requires peroxisome proliferator-activated receptor alpha in mice. Neurosci. Lett. 2003, 352(3):203-206.
258. Liu Y.G., Wang X.D., Zhang X.B. [Effects of resveratrol on inflammatory process induced by focal cerebral ischemia-reperfusion in rats]. Zhongguo Zhong Yao Za Zhi 2007, 32(17):1792-1795.
259. Gao D., Zhang X., Jiang X., Peng Y., Huang W., Cheng G., Song L. Resveratrol reduces the elevated level of MMP-9 induced by cerebral ischemia-reperfusion in mice. Life Sci. 2006, 78(22):2564-2570.
260. Tsai S.K., Hung L.M., Fu Y.T., Cheng H., Nien M.W., Liu H.Y., Zhang F.B., Huang S.S. Resveratrol neuroprotective effects during focal cerebral ischemia injury via nitric oxide mechanism in rats. J. Vasc. Surg. 2007, 46(2):346-353.
261. Dong W., Li N., Gao D., Zhen H., Zhang X., Li F. Resveratrol attenuates ischemic brain damage in the delayed phase after stroke and induces messenger RNA and protein express for angiogenic factors. J. Vasc. Surg. 2008, 48(3):709-714.
262. Krishnan V., Nestler E.J. Animal models of depression: molecular perspectives. Curr. Top. Behav. Neurosci. 2011, 7:121-147.
263. Carboni L. Peripheral biomarkers in animal models of major depressive disorder. Dis. Markers 2013, 35(1):33-41.
264. Hurley L.L., Akinfiresoye L., Kalejaiye O., Tizabi Y. Antidepressant effects of resveratrol in an animal model of depression. Behav. Brain Res. 2014, 268:1-7.
265. Huang W., Chen Z., Wang Q., Lin M., Wu S., Yan Q., Wu F., Yu X., Xie X., Li G., et al. Piperine potentiates the antidepressant-like effect of trans-resveratrol: involvement of monoaminergic system. Metab. Brain Dis. 2013, 28(4):585-595.
266. Xu Y., Wang Z., You W., Zhang X., Li S., Barish P.A., Vernon M.M., Du X., Li G., Pan J., et al. Antidepressant-like effect of trans-resveratrol: Involvement of serotonin and noradrenaline system. Eur. Neuropsychopharmacol. 2010, 20(6):405-413.
267. Ge J.F., Peng L., Cheng J.Q., Pan C.X., Tang J., Chen F.H., Li J. Antidepressant-like effect of resveratrol: involvement of antioxidant effect and peripheral regulation on HPA axis. Pharmacol. Biochem. Behav. 2013, 114-115:64-69.
268. Yu Y., Wang R., Chen C., Du X., Ruan L., Sun J., Li J., Zhang L., O'Donnell J.M., Pan J., et al. Antidepressant-like effect of trans-resveratrol in chronic stress model: behavioral and neurochemical evidences. J. Psychiatr. Res. 2013, 47(3):315-322.
269. Wang Z., Gu J., Wang X., Xie K., Luan Q., Wan N., Zhang Q., Jiang H., Liu D. Antidepressant-like activity of resveratrol treatment in the forced swim test and tail suspension test in mice: the HPA axis, BDNF expression and phosphorylation of ERK. Pharmacol. Biochem. Behav. 2013, 112:104-110.
270. Liu D., Zhang Q., Gu J., Wang X., Xie K., Xian X., Wang J., Jiang H., Wang Z. Resveratrol prevents impaired cognition induced by chronic unpredictable mild stress in rats. Prog. Neuropsychopharmacol. Biol. Psychiatry 2014, 49:21-29.
271. Hui Yin Y., Ahmad N., Makmor-Bakry M. Pathogenesis of epilepsy: challenges in animal models. Iran J. Basic Med. Sci. 2013, 16(11):1119-1132.
272. Meng X.J., Wang F., Li C.K. Resveratrol is neuroprotective and improves cognition in pentylenetetrazole-kindling model of epilepsy in rats. Indian J. Pharm. Sci. 2014, 76(2):125-131.
273. Saha L., Chakrabarti A. Understanding the anti-kindling role and its mechanism of Resveratrol in Pentylenetetrazole induced-kindling in a rat model. Pharmacol. Biochem. Behav. 2014, 120:57-64.
274. Wu Z., Xu Q., Zhang L., Kong D., Ma R., Wang L. Protective effect of resveratrol against kainate-induced temporal lobe epilepsy in rats. Neurochem. Res. 2009, 34(8):1393-1400.
275. Friedman L.K., Goldstein B., Rafiuddin A., Roblejo P., Friedman S. Lack of resveratrol neuroprotection in developing rats treated with kainic acid. Neuroscience 2013, 230:39-49.
276. Porquet D., Casadesús G., Bayod S., Vicente A., Canudas A.M., Vilaplana J., Pelegrí C., Sanfeliu C., Camins A., Pallàs M., et al. Dietary resveratrol prevents Alzheimer's markers and increases life span in SAMP8. Age (Dordr.) 2013, 35(5):1851-1865.
277. Chang J., Rimando A., Pallas M., Camins A., Porquet D., Reeves J., Shukitt-Hale B., Smith M.A., Joseph J.A., Casadesus G. Low-dose pterostilbene, but not resveratrol, is a potent neuromodulator in aging and Alzheimer's disease. Neurobiol. Aging 2012, 33(9):2062-2071.
278. Huang T.C., Lu K.T., Wo Y.Y., Wu Y.J., Yang Y.L. Resveratrol protects rats from Aβ-induced neurotoxicity by the reduction of iNOS expression and lipid peroxidation. PLoS ONE 2011, 6(12):e29102.
279. Vingtdeux V., Giliberto L., Zhao H., Chandakkar P., Wu Q., Simon J.E., Janle E.M., Lobo J., Ferruzzi M.G., Davies P., et al. AMP-activated protein kinase signaling activation by resveratrol modulates amyloid-beta peptide metabolism. J. Biol. Chem. 2010, 285(12):9100-9113.
280. Varamini B., Sikalidis A.K., Bradford K.L. Resveratrol increases cerebral glycogen synthase kinase phosphorylation as well as protein levels of drebrin and transthyretin in mice: an exploratory study. Int. J. Food Sci. Nutr. 2014, 65(1):89-96.
281. Ramaswamy S., McBride J.L., Kordower J.H. Animal models of Huntington's disease. ILAR J. 2007, 48(4):356-373.
282. Ho D.J., Calingasan N.Y., Wille E., Dumont M., Beal M.F. Resveratrol protects against peripheral deficits in a mouse model of Huntington's disease. Exp. Neurol. 2010, 225(1):74-84.
283. Blesa J., Phani S., Jackson-Lewis V., Przedborski S. Classic and new animal models of Parkinson's disease. J. Biomed. Biotechnol. 2012, 2012:845618.
284. Mudò G., Mäkelä J., Di Liberto V., Tselykh T.V., Olivieri M., Piepponen P., Eriksson O., Mälkiä A., Bonomo A., Kairisalo M., et al. Transgenic expression and activation of PGC-1α protect dopaminergic neurons in the MPTP mouse model of Parkinson's disease. Cell. Mol. Life Sci. 2012, 69(7):1153-1165.
285. Wang Y., Xu H., Fu Q., Ma R., Xiang J. [Resveratrol derived from rhizoma et radix polygoni cuspidati and its liposomal form protect nigral cells of Parkinsonian rats]. Zhongguo Zhong Yao Za Zhi 2011, 36(8):1060-1066.
286. Wang Y., Xu H., Fu Q., Ma R., Xiang J. Protective effect of resveratrol derived from Polygonum cuspidatum and its liposomal form on nigral cells in parkinsonian rats. J. Neurol. Sci. 2011, 304(1-2):29-34.
287. Khan M.M., Ahmad A., Ishrat T., Khan M.B., Hoda M.N., Khuwaja G., Raza S.S., Khan A., Javed H., Vaibhav K., et al. Resveratrol attenuates 6-hydroxydopamine-induced oxidative damage and dopamine depletion in rat model of Parkinson's disease. Brain Res. 2010, 1328:139-151.
288. Gerhardt E., Gräber S., Szego E.M., Moisoi N., Martins L.M., Outeiro T.F., Kermer P. Idebenone and resveratrol extend lifespan and improve motor function of HtrA2 knockout mice. PLoS ONE 2011, 6(12):e28855.
289. Srivastava G., Dixit A., Yadav S., Patel D.K., Prakash O., Singh M.P. Resveratrol potentiates cytochrome P450 2 d22-mediated neuroprotection in maneb- and paraquat-induced parkinsonism in the mouse. Free Radic. Biol. Med. 2012, 52(8):1294-1306.
290. Zhao Y.N., Li W.F., Li F., Zhang Z., Dai Y.D., Xu A.L., Qi C., Gao J.M., Gao J. Resveratrol improves learning and memory in normally aged mice through microRNA-CREB pathway. Biochem. Biophys. Res. Commun. 2013, 435(4):597-602.
291. Oomen C.A., Farkas E., Roman V., van der Beek E.M., Luiten P.G., Meerlo P. Resveratrol preserves cerebrovascular density and cognitive function in aging mice. Front. Aging Neurosci. 2009, 1:4.
292. Tiwari V., Chopra K. Resveratrol abrogates alcohol-induced cognitive deficits by attenuating oxidative-nitrosative stress and inflammatory cascade in the adult rat brain. Neurochem. Int. 2013, 62(6):861-869.
293. Tiwari V., Chopra K. Resveratrol prevents alcohol-induced cognitive deficits and brain damage by blocking inflammatory signaling and cell death cascade in neonatal rat brain. J. Neurochem. 2011, 117(4):678-690.
294. Koz S.T., Etem E.O., Baydas G., Yuce H., Ozercan H.I., Kuloğlu T., Koz S., Etem A., Demir N. Effects of resveratrol on blood homocysteine level, on homocysteine induced oxidative stress, apoptosis and cognitive dysfunctions in rats. Brain Res. 2012, 1484:29-38.
295. Liu G.S., Zhang Z.S., Yang B., He W. Resveratrol attenuates oxidative damage and ameliorates cognitive impairment in the brain of senescence-accelerated mice. Life Sci. 2012, 91(17-18):872-877.
296. Zhao H., Niu Q., Li X., Liu T., Xu Y., Han H., Wang W., Fan N., Tian Q., Zhang H., et al. Long-term resveratrol consumption protects ovariectomized rats chronically treated with D-galactose from developing memory decline without effects on the uterus. Brain Res. 2012, 1467:67-80.
297. Girbovan C., Morin L., Plamondon H. Repeated resveratrol administration confers lasting protection against neuronal damage but induces dose-related alterations of behavioral impairments after global ischemia. Behav. Pharmacol. 2012, 23(1):1-13.
298. Karalis F., Soubasi V., Georgiou T., Nakas C.T., Simeonidou C., Guiba-Tziampiri O., Spandou E. Resveratrol ameliorates hypoxia/ischemia-induced behavioral deficits and brain injury in the neonatal rat brain. Brain Res. 2011, 1425:98-110.
299. Gacar N., Mutlu O., Utkan T., Komsuoglu Celikyurt I., Gocmez S.S., Ulak G. Beneficial effects of resveratrol on scopolamine but not mecamylamine induced memory impairment in the passive avoidance and Morris water maze tests in rats. Pharmacol. Biochem. Behav. 2011, 99(3):316-323.
300. Dal-Pan A., Pifferi F., Marchal J., Picq J.L., Aujard F., Consortium R. Cognitive performances are selectively enhanced during chronic caloric restriction or resveratrol supplementation in a primate. PLoS ONE 2011, 6(1):e16581.
301. Park H.R., Kong K.H., Yu B.P., Mattson M.P., Lee J. Resveratrol inhibits the proliferation of neural progenitor cells and hippocampal neurogenesis. J. Biol. Chem. 2012, 287(51):42588-42600.
302. Li W., Jiang D. Effect of resveratrol on Bcl-2 and VEGF expression in oxygen-induced retinopathy of prematurity. J. Pediatr. Ophthalmol. Strabismus 2012, 49(4):230-235.
303. Kubota S., Kurihara T., Ebinuma M., Kubota M., Yuki K., Sasaki M., Noda K., Ozawa Y., Oike Y., Ishida S., et al. Resveratrol prevents light-induced retinal degeneration via suppressing activator protein-1 activation. Am. J. Pathol. 2010, 177(4):1725-1731.
304. Kim W.T., Suh E.S. Retinal protective effects of resveratrol via modulation of nitric oxide synthase on oxygen-induced retinopathy. Korean J. Ophthalmol. 2010, 24(2):108-118.
305. Liu X.Q., Wu B.J., Pan W.H., Zhang X.M., Liu J.H., Chen M.M., Chao F.P., Chao H.M. Resveratrol mitigates rat retinal ischemic injury: the roles of matrix metalloproteinase-9, inducible nitric oxide, and heme oxygenase-1. J. Ocul. Pharmacol. Ther. 2013, 29(1):33-40.
306. Vin A.P., Hu H., Zhai Y., Von Zee C.L., Logeman A., Stubbs E.B., Perlman J.I., Bu P. Neuroprotective effect of resveratrol prophylaxis on experimental retinal ischemic injury. Exp. Eye Res. 2013, 108:72-75.
307. Li C., Wang L., Huang K., Zheng L. Endoplasmic reticulum stress in retinal vascular degeneration: protective role of resveratrol. Invest. Ophthalmol. Vis. Sci. 2012, 53(6):3241-3249.
308. Sheu S.J., Liu N.C., Ou C.C., Bee Y.S., Chen S.C., Lin H.C., Chan J.Y. Resveratrol stimulates mitochondrial bioenergetics to protect retinal pigment epithelial cells from oxidative damage. Invest. Ophthalmol. Vis. Sci. 2013, 54(9):6426-6438.
309. Doganay S., Firat P.G., Cankaya C., Kirimlioglu H. Evaluation of the effects of resveratrol and bevacizumab on experimental corneal alkali burn. Burns 2013, 39(2):326-330.
310. Bazzo K.O., Souto A.A., Lopes T.G., Zanin R.F., Gomez M.V., Souza A.H., Campos M.M. Evidence for the analgesic activity of resveratrol in acute models of nociception in mice. J. Nat. Prod. 2013, 76(1):13-21.
311. Tillu D.V., Melemedjian O.K., Asiedu M.N., Qu N., De Felice M., Dussor G., Price T.J. Resveratrol engages AMPK to attenuate ERK and mTOR signaling in sensory neurons and inhibits incision-induced acute and chronic pain. Mol. Pain 2012, 8:5.
312. Yin Q., Lu F.F., Zhao Y., Cheng M.Y., Fan Q., Cui J., Liu L., Cheng W., Yan C.D. Resveratrol facilitates pain attenuation in a rat model of neuropathic pain through the activation of spinal Sirt1. Reg. Anesth. Pain Med. 2013, 38(2):93-99.
313. Shao H., Xue Q., Zhang F., Luo Y., Zhu H., Zhang X., Zhang H., Ding W., Yu B. Spinal SIRT1 activation attenuates neuropathic pain in mice. PLoS ONE 2014, 9(6):e100938.
314. Tsai R.Y., Chou K.Y., Shen C.H., Chien C.C., Tsai W.Y., Huang Y.N., Tao P.L., Lin Y.S., Wong C.S. Resveratrol regulates N-methyl-D-aspartate receptor expression and suppresses neuroinflammation in morphine-tolerant rats. Anesth. Analg. 2012, 115(4):944-952.
315. Satomoto M., Itoh H., Uchida A., Makita K. [Resveratrol did not prevent sevoflurane-induced neuroapoptosis in the neonatal mice brain]. Masui 2013, 62(10):1184-1187.
316. Sahu S.S., Madhyastha S., Rao G.M. Neuroprotective effect of resveratrol against prenatal stress induced cognitive impairment and possible involvement of Na(+), K(+)-ATPase activity. Pharmacol. Biochem. Behav. 2013, 103(3):520-525.
317. Kumar A., Singh C.K., Lavoie H.A., Dipette D.J., Singh U.S. Resveratrol restores Nrf2 level and prevents ethanol-induced toxic effects in the cerebellum of a rodent model of fetal alcohol spectrum disorders. Mol. Pharmacol. 2011, 80(3):446-457.
318. Han S., Choi J.R., Soon Shin K., Kang S.J. Resveratrol upregulated heat shock proteins and extended the survival of G93A-SOD1 mice. Brain Res. 2012, 1483:112-117.
319. Busanello A., Peroza L.R., Wagner C., Sudati J.H., Pereira R.P., Prestes AeS, Rocha J.B., Fachinetto R., Barbosa N.B. Resveratrol reduces vacuous chewing movements induced by acute treatment with fluphenazine. Pharmacol. Biochem. Behav. 2012, 101(2):307-310.
320. Saha A., Sarkar C., Singh S.P., Zhang Z., Munasinghe J., Peng S., Chandra G., Kong E., Mukherjee A.B. The blood-brain barrier is disrupted in a mouse model of infantile neuronal ceroid lipofuscinosis: amelioration by resveratrol. Hum. Mol. Genet. 2012, 21(10):2233-2244.
321. Moriya J., Chen R., Yamakawa J., Sasaki K., Ishigaki Y., Takahashi T. Resveratrol improves hippocampal atrophy in chronic fatigue mice by enhancing neurogenesis and inhibiting apoptosis of granular cells. Biol. Pharm. Bull. 2011, 34(3):354-359.
322. Liu C., Shi Z., Fan L., Zhang C., Wang K., Wang B. Resveratrol improves neuron protection and functional recovery in rat model of spinal cord injury. Brain Res. 2011, 1374:100-109.
323. Rahvar M., Nikseresht M., Shafiee S.M., Naghibalhossaini F., Rasti M., Panjehshahin M.R., Owji A.A. Effect of oral resveratrol on the BDNF gene expression in the hippocampus of the rat brain. Neurochem. Res. 2011, 36(5):761-765.
324. Shin J.A., Lee H., Lim Y.K., Koh Y., Choi J.H., Park E.M. Therapeutic effects of resveratrol during acute periods following experimental ischemic stroke. J. Neuroimmunol. 2010, 227(1-2):93-100.
325. Simão F., Matté A., Breier A.C., Kreutz F., Trindade V.M., Netto C.A., Salbego C.G. Resveratrol prevents global cerebral ischemia-induced decrease in lipid content. Neurol. Res. 2013, 35(1):59-64.
326. Simão F., Matté A., Matté C., Soares F.M., Wyse A.T., Netto C.A., Salbego C.G. Resveratrol prevents oxidative stress and inhibition of Na(+)K(+)-ATPase activity induced by transient global cerebral ischemia in rats. J. Nutr. Biochem. 2011, 22(10):921-928.
327. Clark D., Tuor U.I., Thompson R., Institoris A., Kulynych A., Zhang X., Kinniburgh D.W., Bari F., Busija D.W., Barber P.A. Protection against recurrent stroke with resveratrol: endothelial protection. PLoS ONE 2012, 7(10):e47792.
328. Baron S., Bedarida T., Cottart C.H., Vibert F., Vessieres E., Ayer A., Henrion D., Hommeril B., Paul J.L., Renault G., et al. Dual effects of resveratrol on arterial damage induced by insulin resistance in aged mice. J. Gerontol. A Biol. Sci. Med. Sci. 2014, 69(3):260-269.
329. Wong Y.T., Gruber J., Jenner A.M., Tay F.E., Ruan R. Chronic resveratrol intake reverses pro-inflammatory cytokine profile and oxidative DNA damage in ageing hybrid mice. Age (Dordr.) 2011, 33(3):229-246.
330. Price N.L., Gomes A.P., Ling A.J., Duarte F.V., Martin-Montalvo A., North B.J., Agarwal B., Ye L., Ramadori G., Teodoro J.S., et al. SIRT1 is required for AMPK activation and the beneficial effects of resveratrol on mitochondrial function. Cell Metab. 2012, 15(5):675-690.
331. da Luz P.L., Tanaka L., Brum P.C., Dourado P.M., Favarato D., Krieger J.E., Laurindo F.R. Red wine and equivalent oral pharmacological doses of resveratrol delay vascular aging but do not extend life span in rats. Atherosclerosis 2012, 224(1):136-142.
332. Tung B.T., Rodríguez-Bies E., Ballesteros-Simarro M., Motilva V., Navas P., López-Lluch G. Modulation of endogenous antioxidant activity by resveratrol and exercise in mouse liver is age dependent. J. Gerontol. A Biol. Sci. Med. Sci. 2014, 69(4):398-409.
333. Akar F., Pektas M.B., Tufan C., Soylemez S., Sepici A., Ulus A.T., Gokalp B., Ozturk K., Surucu H.S. Resveratrol shows vasoprotective effect reducing oxidative stress without affecting metabolic disturbances in insulin-dependent diabetes of rabbits. Cardiovasc. Drugs Ther. 2011, 25(2):119-131.
334. Hsu S.C., Huang S.M., Chen A., Sun C.Y., Lin S.H., Chen J.S., Liu S.T., Hsu Y.J. Resveratrol increases anti-aging Klotho gene expression via the activating transcription factor 3/c-Jun complex-mediated signaling pathway. Int. J. Biochem. Cell Biol. 2014, 53:361-371.
335. Strong R., Miller R.A., Astle C.M., Baur J.A., de Cabo R., Fernandez E., Guo W., Javors M., Kirkland J.L., Nelson J.F., et al. Evaluation of resveratrol, green tea extract, curcumin, oxaloacetic acid, and medium-chain triglyceride oil on life span of genetically heterogeneous mice. J. Gerontol. A Biol. Sci. Med. Sci. 2013, 68(1):6-16.
336. Miller R.A., Harrison D.E., Astle C.M., Baur J.A., Boyd A.R., de Cabo R., Fernandez E., Flurkey K., Javors M.A., Nelson J.F., et al. Rapamycin, but not resveratrol or simvastatin, extends life span of genetically heterogeneous mice. J. Gerontol. A Biol. Sci. Med. Sci. 2011, 66(2):191-201.
337. Labbé A., Garand C., Cogger V.C., Paquet E.R., Desbiens M., Le Couteur D.G., Lebel M. Resveratrol improves insulin resistance hyperglycemia and hepatosteatosis but not hypertriglyceridemia, inflammation, and life span in a mouse model for Werner syndrome. J. Gerontol. A Biol. Sci. Med. Sci. 2011, 66(3):264-278.
338. Liu M., Yin Y., Ye X., Zeng M., Zhao Q., Keefe D.L., Liu L. Resveratrol protects against age-associated infertility in mice. Hum. Reprod. 2013, 28(3):707-717.
339. Soner B.C., Murat N., Demir O., Guven H., Esen A., Gidener S. Evaluation of vascular smooth muscle and corpus cavernosum on hypercholesterolemia. Is resveratrol promising on erectile dysfunction?. Int. J. Impot. Res. 2010, 22(4):227-233.
340. Ergenoğlu A.M., Yeniel A., Erbaş O., Aktuğ H., Yildirim N., Ulukuş M., Taskiran D. Regression of endometrial implants by resveratrol in an experimentally induced endometriosis model in rats. Reprod. Sci. 2013, 20(10):1230-1236.
341. Rudzitis-Auth J., Menger M.D., Laschke M.W. Resveratrol is a potent inhibitor of vascularization and cell proliferation in experimental endometriosis. Hum. Reprod. 2013, 28(5):1339-1347.
342. Roberts V.H., Pound L.D., Thorn S.R., Gillingham M.B., Thornburg K.L., Friedman J.E., Frias A.E., Grove K.L. Beneficial and cautionary outcomes of resveratrol supplementation in pregnant nonhuman primates. FASEB J. 2014, 28(6):2466-2477.
343. Zhang H., Zhai Z., Wang Y., Zhang J., Wu H., Li C., Li D., Lu L., Wang X., Chang J., et al. Resveratrol ameliorates ionizing irradiation-induced long-term hematopoietic stem cell injury in mice. Free Radic. Biol. Med. 2013, 54:40-50.
344. Şimşek G., Gürocak S., Karadağ N., Karabulut A.B., Demirtaş E., Karataş E., Pepele E. Protective effects of resveratrol on salivary gland damage induced by total body irradiation in rats. Laryngoscope 2012, 122(12):2743-2748.
345. Patel K.R., Brown V.A., Jones D.J., Britton R.G., Hemingway D., Miller A.S., West K.P., Booth T.D., Perloff M., Crowell J.A., et al. Clinical pharmacology of resveratrol and its metabolites in colorectal cancer patients. Cancer Res. 2010, 70(19):7392-7399.
346. Howells L.M., Berry D.P., Elliott P.J., Jacobson E.W., Hoffmann E., Hegarty B., Brown K., Steward W.P., Gescher A.J. Phase I randomized, double-blind pilot study of micronized resveratrol (SRT501) in patients with hepatic metastases-safety, pharmacokinetics, and pharmacodynamics. Cancer Prev. Res. (Phila.) 2011, 4(9):1419-1425.
347. Zhu W., Qin W., Zhang K., Rottinghaus G.E., Chen Y.C., Kliethermes B., Sauter E.R. Trans-resveratrol alters mammary promoter hypermethylation in women at increased risk for breast cancer. Nutr. Cancer 2012, 64(3):393-400.
348. Chow H.H., Garland L.L., Hsu C.H., Vining D.R., Chew W.M., Miller J.A., Perloff M., Crowell J.A., Alberts D.S. Resveratrol modulates drug- and carcinogen-metabolizing enzymes in a healthy volunteer study. Cancer Prev. Res. (Phila.) 2010, 3(9):1168-1175.
349. Magyar K., Halmosi R., Palfi A., Feher G., Czopf L., Fulop A., Battyany I., Sumegi B., Toth K., Szabados E. Cardioprotection by resveratrol: A human clinical trial in patients with stable coronary artery disease. Clin. Hemorheol. Microcirc. 2012, 50(3):179-187.
350. Tomé-Carneiro J., Gonzálvez M., Larrosa M., García-Almagro F.J., Avilés-Plaza F., Parra S., Yáñez-Gascón M.J., Ruiz-Ros J.A., García-Conesa M.T., Tomás-Barberán F.A., et al. Consumption of a grape extract supplement containing resveratrol decreases oxidized LDL and ApoB in patients undergoing primary prevention of cardiovascular disease: a triple-blind, 6-month follow-up, placebo-controlled, randomized trial. Mol. Nutr. Food Res. 2012, 56(5):810-821.
351. Tomé-Carneiro J., Gonzálvez M., Larrosa M., Yáñez-Gascón M.J., García-Almagro F.J., Ruiz-Ros J.A., García-Conesa M.T., Tomás-Barberán F.A., Espín J.C. One-year consumption of a grape nutraceutical containing resveratrol improves the inflammatory and fibrinolytic status of patients in primary prevention of cardiovascular disease. Am. J. Cardiol. 2012, 110(3):356-363.
352. Zamora-Ros R., Urpi-Sarda M., Lamuela-Raventós R.M., Martínez-González M., Salas-Salvadó J., Arós F., Fitó M., Lapetra J., Estruch R., Andres-Lacueva C., et al. High urinary levels of resveratrol metabolites are associated with a reduction in the prevalence of cardiovascular risk factors in high-risk patients. Pharmacol. Res. 2012, 65(6):615-620.
353. Tomé-Carneiro J., Gonzálvez M., Larrosa M., Yáñez-Gascón M.J., García-Almagro F.J., Ruiz-Ros J.A., Tomás-Barberán F.A., García-Conesa M.T., Espín J.C. Grape resveratrol increases serum adiponectin and downregulates inflammatory genes in peripheral blood mononuclear cells: a triple-blind, placebo-controlled, one-year clinical trial in patients with stable coronary artery disease. Cardiovasc. Drugs Ther. 2013, 27(1):37-48.
354. Gliemann L., Schmidt J.F., Olesen J., Biensø R.S., Peronard S.L., Grandjean S.U., Mortensen S.P., Nyberg M., Bangsbo J., Pilegaard H., et al. Resveratrol blunts the positive effects of exercise training on cardiovascular health in aged men. J. Physiol. 2013, 591(Pt 20):5047-5059.
355. Agarwal B., Campen M.J., Channell M.M., Wherry S.J., Varamini B., Davis J.G., Baur J.A., Smoliga J.M. Resveratrol for primary prevention of atherosclerosis: clinical trial evidence for improved gene expression in vascular endothelium. Int. J. Cardiol. 2013, 166(1):246-248.
356. Brasnyó P., Molnár G.A., Mohás M., Markó L., Laczy B., Cseh J., Mikolás E., Szijártó I.A., Mérei A., Halmai R., et al. Resveratrol improves insulin sensitivity, reduces oxidative stress and activates the Akt pathway in type 2 diabetic patients. Br. J. Nutr. 2011, 106(3):383-389.
357. Bhatt J.K., Thomas S., Nanjan M.J. Resveratrol supplementation improves glycemic control in type 2 diabetes mellitus. Nutr. Res. 2012, 32(7):537-541.
358. Crandall J.P., Oram V., Trandafirescu G., Reid M., Kishore P., Hawkins M., Cohen H.W., Barzilai N. Pilot study of resveratrol in older adults with impaired glucose tolerance. J. Gerontol. A Biol. Sci. Med. Sci. 2012, 67(12):1307-1312.
359. Poulsen M.M., Vestergaard P.F., Clasen B.F., Radko Y., Christensen L.P., Stødkilde-Jørgensen H., Møller N., Jessen N., Pedersen S.B., Jørgensen J.O. High-dose resveratrol supplementation in obese men: an investigator-initiated, randomized, placebo-controlled clinical trial of substrate metabolism, insulin sensitivity, and body composition. Diabetes 2013, 62(4):1186-1195.
360. Tomé-Carneiro J., Larrosa M., Yáñez-Gascón M.J., Dávalos A., Gil-Zamorano J., Gonzálvez M., García-Almagro F.J., Ruiz Ros J.A., Tomás-Barberán F.A., Espín J.C., et al. One-year supplementation with a grape extract containing resveratrol modulates inflammatory-related microRNAs and cytokines expression in peripheral blood mononuclear cells of type 2 diabetes and hypertensive patients with coronary artery disease. Pharmacol. Res. 2013, 72:69-82.
361. Bashmakov Y.K., Assaad-Khalil S.H., Abou Seif M., Udumyan R., Megallaa M., Rohoma K.H., Zeitoun M., Petyaev I.M. Resveratrol promotes foot ulcer size reduction in type 2 diabetes patients. ISRN Endocrinol. 2014, 2014:816307.
362. Movahed A., Nabipour I., Lieben Louis X., Thandapilly S.J., Yu L., Kalantarhormozi M., Rekabpour S.J., Netticadan T. Antihyperglycemic effects of short term resveratrol supplementation in type 2 diabetic patients. Evid. Based Complement. Alternat. Med. 2013, 2013:851267.
363. Wong R.H., Howe P.R., Buckley J.D., Coates A.M., Kunz I., Berry N.M. Acute resveratrol supplementation improves flow-mediated dilatation in overweight/obese individuals with mildly elevated blood pressure. Nutr. Metab. Cardiovasc. Dis. 2011, 21(11):851-856.
364. Timmers S., Konings E., Bilet L., Houtkooper R.H., van de Weijer T., Goossens G.H., Hoeks J., van der Krieken S., Ryu D., Kersten S., et al. Calorie restriction-like effects of 30days of resveratrol supplementation on energy metabolism and metabolic profile in obese humans. Cell Metab. 2011, 14(5):612-622.
365. Yoshino J., Conte C., Fontana L., Mittendorfer B., Imai S., Schechtman K.B., Gu C., Kunz I., Rossi Fanelli F., Patterson B.W., et al. Resveratrol supplementation does not improve metabolic function in nonobese women with normal glucose tolerance. Cell Metab. 2012, 16(5):658-664.
366. De Groote D., Van Belleghem K., Devière J., Van Brussel W., Mukaneza A., Amininejad L. Effect of the intake of resveratrol, resveratrol phosphate, and catechin-rich grape seed extract on markers of oxidative stress and gene expression in adult obese subjects. Ann. Nutr. Metab. 2012, 61(1):15-24.
367. Wong R.H., Berry N.M., Coates A.M., Buckley J.D., Bryan J., Kunz I., Howe P.R. Chronic resveratrol consumption improves brachial flow-mediated dilatation in healthy obese adults. J. Hypertens. 2013, 31(9):1819-1827.
368. Knop F.K., Konings E., Timmers S., Schrauwen P., Holst J.J., Blaak E.E. Thirty days of resveratrol supplementation does not affect postprandial incretin hormone responses, but suppresses postprandial glucagon in obese subjects. Diabet. Med. 2013, 30(10):1214-1218.
369. Dash S., Xiao C., Morgantini C., Szeto L., Lewis G.F. High-dose resveratrol treatment for 2weeks inhibits intestinal and hepatic lipoprotein production in overweight/obese men. Arterioscler. Thromb. Vasc. Biol. 2013, 33(12):2895-2901.
370. Witte A.V., Kerti L., Margulies D.S., Flöel A. Effects of resveratrol on memory performance, hippocampal functional connectivity, and glucose metabolism in healthy older adults. J. Neurosci. 2014, 34(23):7862-7870.
371. Kennedy D.O., Wightman E.L., Reay J.L., Lietz G., Okello E.J., Wilde A., Haskell C.F. Effects of resveratrol on cerebral blood flow variables and cognitive performance in humans: a double-blind, placebo-controlled, crossover investigation. Am. J. Clin. Nutr. 2010, 91(6):1590-1597.
372. Fabbrocini G., Staibano S., De Rosa G., Battimiello V., Fardella N., Ilardi G., La Rotonda M.I., Longobardi A., Mazzella M., Siano M., et al. Resveratrol-containing gel for the treatment of acne vulgaris: a single-blind, vehicle-controlled, pilot study. Am. J. Clin. Dermatol. 2011, 12(2):133-141.
373. Maia H., Haddad C., Pinheiro N., Casoy J. Advantages of the association of resveratrol with oral contraceptives for management of endometriosis-related pain. Int. J. Womens Health 2012, 4:543-549.
374. Bo S., Ciccone G., Castiglione A., Gambino R., De Michieli F., Villois P., Durazzo M., Cavallo-Perin P., Cassader M. Anti-inflammatory and antioxidant effects of resveratrol in healthy smokers a randomized, double-blind, placebo-controlled, cross-over trial. Curr. Med. Chem. 2013, 20(10):1323-1331.
375. Militaru C., Donoiu I., Craciun A., Scorei I.D., Bulearca A.M., Scorei R.I. Oral resveratrol and calcium fructoborate supplementation in subjects with stable angina pectoris: effects on lipid profiles, inflammation markers, and quality of life. Nutrition 2013, 29(1):178-183.
376. Semba R.D., Ferrucci L., Bartali B., Urpí-Sarda M., Zamora-Ros R., Sun K., Cherubini A., Bandinelli S., Andres-Lacueva C. Resveratrol levels and all-cause mortality in older community-dwelling adults. JAMA Intern. Med. 2014, 174(7):1077-1084.
377. Johnson J.J., Nihal M., Siddiqui I.A., Scarlett C.O., Bailey H.H., Mukhtar H., Ahmad N. Enhancing the bioavailability of resveratrol by combining it with piperine. Mol. Nutr. Food Res. 2011, 55(8):1169-1176.
378. Wightman E.L., Reay J.L., Haskell C.F., Williamson G., Dew T.P., Kennedy D.O. Effects of resveratrol alone or in combination with piperine on cerebral blood flow parameters and cognitive performance in human subjects: a randomised, double-blind, placebo-controlled, cross-over investigation. Br. J. Nutr. 2014, 112(2):203-213.
379. Pezzuto J.M. The phenomenon of resveratrol: redefining the virtues of promiscuity. Ann. N. Y. Acad. Sci. 2011, 1215:123-130.
380. He X.P., Deng Q., Cai L., Wang C.Z., Zang Y., Li J., Chen G.R., Tian H. Fluorogenic resveratrol-confined graphene oxide for economic and rapid detection of Alzheimer's disease. ACS Appl. Mater. Interfaces 2014, 6(8):5379-5382.
381. Kondratyuk T.P., Park E.J., Marler L.E., Ahn S., Yuan Y., Choi Y., Yu R., van Breemen R.B., Sun B., Hoshino J., et al. Resveratrol derivatives as promising chemopreventive agents with improved potency and selectivity. Mol. Nutr. Food Res. 2011, 55(8):1249-1265.